

The protonmotive force and respiratory control:

Building blocks of mitochondrial physiology

Part 1.

http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2017-09-21

Preprint version 13 (2017-10-26)

MitoEAGLE Network

Corresponding author: Gnaiger E

Contributing co-authors

Ahn B, Alves MG, Amati F, Åsander Frostner E, Bailey DM, Bastos Sant'Anna Silva AC, Battino M, Beard DA, Ben-Shachar D, Bishop D, Breton S, Brown GC, Brown RA, Buettner GR, Carvalho E, Cervinkova Z, Chang SC, Chicco AJ, Coen PM, Collins JL, Crisóstomo L, Davis MS, Dias T, Distefano G, Doerrier C, Ehinger J, Elmer E, Fell DA, Ferko M, Ferreira JCB, Filipovska A, Fisher J, Garcia-Roves PM, Garcia-Souza LF, Genova ML, Gonzalo H, Goodpaster BH, Gorr TA, Han J, Harrison DK, Hellgren KT, Hernansanz P, Holland O, Hoppel CL, Iglesias-Gonzalez J, Irving BA, Iyer S, Jackson CB, Jansen-Dürr P, Jespersen NR, Jha RK, Kaambre T, Kane DA, Kappler L, Keijer J, Komlodi T, Kopitar-Jerala N, Krakovcic N, Kuang J, Labieniec-Watala M, Lai N, Laner V, Lee HK, Lemieux H, Lerfall J, Lucchinetti E, MacMillan-Crow LA, Makrecka-Kuka M, Meszaros AT, Moiso N, Molina AJA, Montaigne D, Moore AL, Murray AJ, Newsom S, Nozickova K, O'Gorman D, Oliveira PF, Oliveira PJ, Orynbayeva Z, Pak YK, Palmeira CM, Patel HH, Pesta D, Petit PX, Pichaud N, Pirkmajer S, Porter RK, Pranger F, Prochownik EV, Radenkovic F, Reboredo P, Renner Sattler K, Robinson MM, Rohlena J, Røslund GV, Rossiter HB, Salvadego D, Scatena R, Schartner M, Scheibye-Knudsen M, Schilling JM, Schlattner U, Schoenfeld P, Scott GR, Singer D, Sobotka O, Spinazzi M, Stier A, Stocker R, Sumbalova Z, Suravajhala P, Tanaka

27 M, Tandler B, Tepp K, Tomar D, Towheed A, Trivigno C, Tronstad KJ, Trougakos IP,
28 Tyrrell DJ, Velika B, Vendelin M, Vercesi AE, Victor VM, Ward ML, Watala C, Wei YH,
29 Wieckowski MR, Wohlwend M, Wolff J, Wuest RCI, Zaugg K, Zaugg M, Zorzano A

30

31 Supporting co-authors:

32 Arandarčikaitė O, Bakker BM, Bernardi P, Boetker HE, Borsheim E, Borutaitė V, Bouitbir J,
33 Calabria E, Calbet JA, Chaurasia B, Clementi E, Coker RH, Collin A, Das AM, De Palma C,
34 Dubouchaud H, Duchon MR, Durham WJ, Dyrstad SE, Engin AB, Fornaro M, Gan Z, Garlid
35 KD, Garten A, Gourlay CW, Granata C, Haas CB, Haavik J, Haendeler J, Hand SC, Hepple
36 RT, Hickey AJ, Hoel F, Kainulainen H, Keppner G, Khamoui AV, Klingenspor M, Koopman
37 WJH, Kowaltowski AJ, Krajcova A, Lenaz G, Malik A, Markova M, Mazat JP, Menze MA,
38 Methner A, Muntané J, Muntean DM, Neuzil J, Oliveira MT, Pallotta ML, Parajuli N,
39 Pettersen IKN, Porter C, Pulinilkunnil T, Ropelle ER, Salin K, Sandi C, Sazanov LA,
40 Siewiera K, Silber AM, Skolik R, Smenes BT, Soares FAA, Sokolova I, Sonkar VK,
41 Stankova P, Swerdlow RH, Szabo I, Trifunovic A, Thyfault JP, Tretter L, Vieyra A, Votion

42 DM, Williams C

43

44 **Updates:**

45 http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2017-09-21

46


Correspondence: Gnaiger E

Department of Visceral, Transplant and Thoracic Surgery, D. Swarovski Research Laboratory, Medical University of Innsbruck, Innrain 66/4, A-6020 Innsbruck, Austria

Email: erich.gnaiger@i-med.ac.at

Tel: +43 512 566796, Fax: +43 512 566796 20

This manuscript on 'The protonmotive force and respiratory control' is a position statement in the frame of COST Action CA15203 MitoEAGLE. The list of co-authors evolved from MitoEAGLE Working Group Meetings and a **bottom-up** spirit of COST in phase 1: This is an open invitation to scientists and students to join as co-authors, to provide a balanced view on mitochondrial respiratory control, a fundamental introductory presentation of the concept of the protonmotive force, and a consensus statement on reporting data of mitochondrial respiration in terms of metabolic flows and fluxes. We plan a series of follow-up reports by the expanding MitoEAGLE Network, to increase the scope of recommendations on harmonization and facilitate global communication and collaboration.



Phase 2: MitoEAGLE preprint (Versions 01 – 10): We continue to invite comments and suggestions on the, particularly if you are an **early career investigator adding an open future-oriented perspective**, or an **established scientist providing a balanced historical basis**. Your critical input into the quality of the manuscript will be most welcome, improving our aims to be educational, general, consensus-oriented, and practically helpful for students working in mitochondrial respiratory physiology.

Phase 3 (2017-11-11): Manuscript submission to a preprint server, such as BioRxiv. We want to invite further opinion leaders: To join as a co-author, please feel free to focus on a particular section in terms of direct input and references, contributing to the scope of the manuscript from the perspective of your expertise. Your comments will be largely posted on the discussion page of the MitoEAGLE preprint website.

If you prefer to submit comments in the format of a referee's evaluation rather than a contribution as a co-author, I will be glad to distribute your views to the updated list of co-authors for a balanced response. We would ask for your consent on this open bottom-up policy.

Phase 4: We organize a MitoEAGLE session linked to our series of reports at the MiPconference Nov 2017 in Hradec Kralove in close association with the MiPsociety (where you hopefully will attend) and at EBEC 2018 in Budapest.

» http://www.mitoeagle.org/index.php/MiP2017_Hradec_Kralove_CZ

I thank you in advance for your feedback.

With best wishes,

Erich Gnaiger

Chair Mitochondrial Physiology Society - <http://www.mitophysiology.org>

Chair COST Action MitoEAGLE - <http://www.mitoeagle.org>

Medical University of Innsbruck, Austria

97	Contents
98	1. Introduction
99	2. Respiratory coupling states in mitochondrial preparations
100	Mitochondrial preparations
101	2.1. <i>Three coupling states of mitochondrial preparations and residual oxygen consumption</i>
102	Coupling control states and respiratory capacities
103	Kinetic control
104	Phosphorylation, P _o
105	LEAK, OXPHOS, ET, ROX
106	2.2. <i>Coupling states and respiratory rates</i>
107	2.3. <i>Classical terminology for isolated mitochondria</i>
108	States 1-5
109	3. The protonmotive force and proton flux
110	3.1. <i>Electric and chemical partial forces versus electrical and chemical units</i>
111	Faraday constant
112	Electrical part of the protonmotive force
113	Chemical part of the protonmotive force
114	3.2. <i>Definitions</i>
115	Control and regulation
116	Respiratory control and response
117	Respiratory coupling control
118	Pathway control states
119	The steady-state
120	3.3. <i>Forces and fluxes in physics and irreversible thermodynamics</i>
121	Vectorial and scalar forces, and fluxes
122	Coupling
123	Coupled versus bound processes
124	4. Normalization: fluxes and flows
125	4.1. <i>Flux per chamber volume</i>
126	4.2. <i>System-specific and sample-specific normalization</i>
127	Extensive quantities
128	Size-specific quantities
129	Molar quantities
130	Flow per system, I
131	Size-specific flux, J
132	Sample concentration, C_{mX}
133	Mass-specific flux, J_{mX,O_2}
134	Number concentration, C_{NX}
135	Flow per sample entity, I_{X,O_2}
136	4.3. <i>Normalization for mitochondrial content</i>
137	Mitochondrial concentration, C_{mte} , and mitochondrial markers
138	Mitochondria-specific flux, J_{mte,O_2}
139	4.4. <i>Conversion: units and normalization</i>
140	4.5. <i>Conversion: oxygen, proton and ATP flux</i>
141	5. Conclusions
142	6. References
143	

144 **Abstract**

145 Clarity of concept and consistency of nomenclature are key trademarks of a research field.
146 These trademarks facilitate effective transdisciplinary communication, education, and
147 ultimately further discovery. As the knowledge base and importance of mitochondrial
148 physiology to human health expand, the necessity for harmonizing nomenclature concerning
149 mitochondrial respiratory states and rates has become increasingly apparent. Peter Mitchell's
150 concept of the protonmotive force establishes the links between electrical and chemical
151 components of energy transformation and coupling in oxidative phosphorylation. This unifying
152 concept provides the framework for developing a consistent nomenclature for mitochondrial
153 physiology and bioenergetics. Herein, we follow IUPAC guidelines on general terms of
154 physical chemistry, extended by the concepts of open systems and irreversible thermodynamics.
155 We align the nomenclature of classical bioenergetics on respiratory states with a concept-driven
156 constructive terminology to address the meaning of each respiratory state. Furthermore, we
157 suggest uniform standards for the evaluation of respiratory states that will ultimately support
158 the development of databases of mitochondrial respiratory function in species, tissues and cells
159 studied under diverse physiological and experimental conditions. In this position statement, in
160 the frame of COST Action CA15203 MitoEAGLE, we endeavour to provide a balanced view
161 on mitochondrial respiratory control, a fundamental introductory presentation of the concept of
162 the protonmotive force, and a critical discussion on reporting data of mitochondrial respiration
163 in terms of metabolic flows and fluxes.

164

165 *Keywords:* Mitochondrial respiratory control, coupling control, mitochondrial
166 preparations, protonmotive force, chemiosmotic theory, oxidative phosphorylation, OXPHOS,
167 efficiency, electron transfer, ET; proton leak, LEAK, residual oxygen consumption, ROX, State
168 2, State 3, State 4, normalization, flow, flux

169

170

171 **Box 1:**

172

173 **In brief:**174 **mitochondria**175 **and Bioblasts**

- * Does the public expect biologists to understand Darwin's theory of evolution?
- * Do students expect that researchers of bioenergetics can explain Mitchell's theory of chemiosmotic energy transformation?

176 **Mitochondria** were described for the first time in 1857 by Rudolph Albert Kölliker as granular177 structures or 'sarkosomes' (*a reference is needed*). In 1886 (*a reference is needed*) Richard

178 Altmann called them 'bioblasts' (published 1894). The word 'mitochondrium' (Greek mitos:

179 thread; chondros: granule) was introduced by Carl Benda (1898). Mitochondria are the oxygen

180 consuming electrochemical generators which evolved from endosymbiotic bacteria (Margulis

181 1970; Lane 2005). The bioblasts of Richard Altmann (1894) included not only the mitochondria

182 as presently defined, but also symbiotic and free-living bacteria.

183 We now recognize mitochondria as dynamic organelles with a double membrane that are

184 contained within eukaryotic cells. The mitochondrial inner membrane (mtIM) shows dynamic

185 tubular to disk-shaped cristae that separate the mitochondrial matrix, *i.e.* the internal

186 mitochondrial compartment, and the intermembrane space; the latter being enclosed by the

187 mitochondrial outer membrane (mtOM). Mitochondria are the structural and functional

188 elemental units of cell respiration. Cell respiration is the consumption of oxygen by electron

189 transfer coupled to electrochemical proton translocation across the mtIM. In the process of

190 oxidative phosphorylation (OXPHOS), the reduction of O₂ is electrochemically coupled to the

191 transformation of energy in the form of adenosine triphosphate (ATP; Mitchell 1961, 2011).

192 These powerhouses of the cell contain the machinery of the OXPHOS-pathway, including

193 transmembrane respiratory complexes (*i.e.* proton pumps with FMN, Fe-S and cytochrome *b*,
194 *c*, *aa*₃ redox systems); alternative dehydrogenases and oxidases; the coenzyme ubiquinone (Q);

195 ATP synthase; the enzymes of the tricarboxylic acid cycle and the fatty acid oxidation enzymes;

196 transporters of ions, metabolites and co-factors; and mitochondrial kinases related to energy

197 transfer pathways. The mitochondrial proteome comprises over 1,200 proteins

198 (MITOCARTA), mostly encoded by nuclear DNA (nDNA), with a variety of functions, many
199 of which are relatively well known (*e.g.* apoptosis-regulating proteins), while others are still
200 under investigation, or need to be identified (*e.g.* alanine transporter).

201 Mitochondria typically maintain several copies of their own genome (hundred to
202 thousands per cell; Cummins 1998), which is almost exclusively maternally inherited (White *et*
203 *al.* 2008) and known as mitochondrial DNA (mtDNA). One exception to strictly maternal
204 inheritance in animals is found in bivalves (Breton *et al.* 2007). mtDNA is 16.5 Kb in length,
205 contains 13 protein-coding genes for subunits of the transmembrane respiratory Complexes CI,
206 CIII, CIV and ATP synthase, and also encodes 22 tRNAs and the mitochondrial 16S and 12S
207 rRNA. The mitochondrial genome is both regulated and supplemented by nuclear-encoded
208 mitochondrial targeted proteins. Evidence has accumulated that additional gene content is
209 encoded in the mitochondrial genome, *e.g.* microRNAs, piRNA, smithRNAs, repeat associated
210 RNA, and even additional proteins (Duarte *et al.* 2014; Lee *et al.* 2015; Cobb *et al.* 2016).

211 The mtIM contains the non-bilayer phospholipid cardiolipin, which is not present in any
212 other eukaryotic cellular membrane. Cardiolipin promotes the formation of respiratory
213 supercomplexes, which are supramolecular assemblies based upon specific, though dynamic,
214 interactions between individual respiratory complexes (Greggio *et al.* 2017; Lenaz *et al.* 2017).
215 Membrane fluidity is an important parameter influencing functional properties of proteins
216 incorporated in the membranes (Waczulikova *et al.* 2007). There is a constant crosstalk between
217 mitochondria and the other cellular components, maintaining cellular mitostasis through
218 regulation at both the transcriptional and post-translational level, and through cell signalling
219 including proteostatic (*e.g.* the ubiquitin-proteasome and autophagy-lysosome pathways) and
220 genome stability modules throughout the cell cycle or even cell death, contributing to
221 homeostatic regulation in response to varying energy demands and stress (Quiros *et al.* 2016).
222 In addition to mitochondrial movement along the microtubules, mitochondrial morphology can
223 change in response to the energy requirements of the cell via processes known as fusion and

224 fission, through which mitochondria can communicate within a network, and in response to
225 intracellular stress factors causing swelling and ultimately permeability transition.

226 Mitochondrial dysfunction is associated with a wide variety of genetic and degenerative
227 diseases. Robust mitochondrial function is supported by physical exercise and caloric balance,
228 and is central for sustained metabolic health throughout life. Therefore, a better understanding
229 of mitochondrial physiology will improve our understanding of the etiology of disease, the
230 diagnostic repertoire of mitochondrial medicine, with a focus on protective medicine, lifestyle
231 and healthy aging.

232 Abbreviation: mt, as generally used in mtDNA. Mitochondrion is singular and
233 mitochondria is plural.

234 *‘For the physiologist, mitochondria afforded the first opportunity for an experimental*
235 *approach to structure-function relationships, in particular those involved in active transport,*
236 *vectorial metabolism, and metabolic control mechanisms on a subcellular level’ (Ernster and*
237 *Schatz 1981).*

238

239 **1. Introduction**

240 Mitochondria are the powerhouses of the cell with numerous physiological, molecular,
241 and genetic functions (**Box 1**). Every study of mitochondrial function and disease is faced with
242 **E**volution, **A**ge, **G**ender and sex, **L**ifestyle, and **E**nvironment (EAGLE) as essential background
243 conditions intrinsic to the individual patient or subject, cohort, species, tissue and to some extent
244 even cell line. As a large and highly coordinated group of laboratories and researchers, the
245 mission of the global MitoEAGLE Network is to generate the necessary scale, type, and quality
246 of consistent data sets and conditions to address this intrinsic complexity. Harmonization of
247 experimental protocols and implementation of a quality control and data management system
248 is required to interrelate results gathered across a spectrum of studies and to generate a
249 rigorously monitored database focused on mitochondrial respiratory function. In this way,

250 researchers within the same and across different disciplines will be positioned to compare their
251 findings to an agreed upon set of clearly defined and accepted international standards.

252 Reliability and comparability of quantitative results depend on the accuracy of
253 measurements under strictly-defined conditions. A conceptually defined framework is also
254 required to warrant meaningful interpretation and comparability of experimental outcomes
255 carried out by research groups at different institutes. With an emphasis on quality of research,
256 collected data can be useful far beyond the specific question of a particular experiment.
257 Enabling meta-analytic studies is the most economic way of providing robust answers to
258 biological questions (Cooper *et al.* 2009). Vague or ambiguous jargon can lead to confusion
259 and may relegate valuable signals to wasteful noise. For this reason, measured values must be
260 expressed in standardized units for each parameter used to define mitochondrial respiratory
261 function. Standardization of nomenclature and definition of technical terms is essential to
262 improve the awareness of the intricate meaning of a divergent scientific vocabulary. The focus
263 on the protonmotive force, coupling states, and fluxes through metabolic pathways of aerobic
264 energy transformation in mitochondrial preparations is a first step in the attempt to generate a
265 harmonized and conceptually-oriented nomenclature in bioenergetics and mitochondrial
266 physiology. Coupling states of intact cells and respiratory control by fuel substrates and specific
267 inhibitors of respiratory enzymes will be reviewed in subsequent communications.

268

269 **2. Respiratory coupling states in mitochondrial preparations**

270 *‘Every professional group develops its own technical jargon for talking about*
271 *matters of critical concern ... People who know a word can share that idea with*
272 *other members of their group, and a shared vocabulary is part of the glue that holds*
273 *people together and allows them to create a shared culture’ (Miller 1991).*

274

275 **Mitochondrial preparations** are defined as either isolated mitochondria, or tissue and
276 cellular preparations in which the barrier function of the plasma membrane is disrupted. The
277 plasma membrane separates the cytosol, nucleus, and organelles (the intracellular
278 compartment) from the environment of the cell. The plasma membrane consists of a lipid
279 bilayer, embedded proteins, and attached organic molecules that collectively control the
280 selective permeability of ions, organic molecules, and particles across the cell boundary. The
281 intact plasma membrane, therefore, prevents the passage of many water-soluble mitochondrial
282 substrates, such as succinate or adenosine diphosphate (ADP), that are required for the analysis
283 of respiratory capacity at kinetically-saturating concentrations, thus limiting the scope of
284 investigations into mitochondrial respiratory function in intact cells. The cholesterol content of
285 the plasma membrane is high compared to mitochondrial membranes. Therefore, mild
286 detergents, such as digitonin and saponin, can be applied to selectively permeabilize the plasma
287 membrane by interaction with cholesterol and allow free exchange of cytosolic components
288 with ions and organic molecules of the immediate cell environment, while maintaining the
289 integrity and localization of organelles, cytoskeleton, and the nucleus. Application of optimum
290 concentrations of these mild detergents leads to the complete loss of cell viability, tested by
291 nuclear staining, while mitochondrial function remains intact, as shown by an unaltered
292 respiration rate of isolated mitochondria after the addition of such low concentrations of digitonin
293 and saponin. In addition to mechanical permeabilization during homogenization of fresh tissue,
294 saponin may be applied to ensure permeabilization of all cells. Crude homogenate and cells
295 permeabilized in the respiration chamber contain all components of the cell at highly diluted
296 concentrations. All mitochondria are retained in chemically-permeabilized mitochondrial
297 preparations and crude tissue homogenates. In the preparation of isolated mitochondria, the
298 cells or tissues are homogenized, and the mitochondria are separated from other cell fractions
299 and purified by differential centrifugation, entailing the loss of a significant fraction of


300 mitochondria. The term mitochondrial preparation does not include further fractionation of
301 mitochondrial components, as well as submitochondrial particles.

302

303 *2.1. Three coupling states of mitochondrial preparations and residual oxygen consumption*


304 **Respiratory capacities in coupling control states:** To extend the classical nomenclature
305 on mitochondrial coupling states (Section 2.4) by a concept-driven terminology that
306 incorporates explicit information on the nature of the respiratory states, the terminology must
307 be general and not restricted to any particular experimental protocol or mitochondrial
308 preparation (Gnaiger 2009). We focus primarily on the conceptual ‘why’, along with
309 clarification of the experimental ‘how’. In the following section, the concept-driven
310 terminology is explained and coupling states are defined. We define respiratory capacities,
311 comparable to channel capacity in information theory (Schneider 2006), as the upper bound of
312 the rate of respiration measured in defined coupling and electron transfer-pathway (ET-
313 pathway) control states. To provide a diagnostic reference for respiratory capacities of core
314 energy metabolism, the capacity of *oxidative phosphorylation*, OXPHOS, is measured at
315 kinetically-saturating concentrations of ADP and inorganic phosphate, P_i . The *oxidative* ET-
316 capacity reveals the limitation of OXPHOS-capacity mediated by the *phosphorylation-*
317 *pathway*. The ET- and phosphorylation-pathways comprise coupled segments of the OXPHOS-
318 pathway. ET-capacity is measured as noncoupled respiration by application of *external*
319 *uncouplers*. The contribution of *intrinsically uncoupled* oxygen consumption is most easily
320 studied in the absence of ADP, *i.e.* by not stimulating phosphorylation, or by inhibition of the
321 phosphorylation-pathway. The corresponding states are collectively classified as LEAK-states,
322 when oxygen consumption compensates mainly for the proton leak (**Table 1**). Different
323 coupling states are induced by (1) adding ADP or P_i , (2) inhibiting the phosphorylation-
324 pathway, and (3) performing uncoupler titrations, while maintaining a defined ET-pathway
325 state with constant fuel substrates and ET inhibitors (**Fig. 1**).

326 **Kinetic control:** Coupling control states are established in the study of mitochondrial
 327 preparations to obtain reference values for various output variables. Physiological conditions *in*
 328 *vivo* may deviate substantially from these experimentally obtained states. Since kinetically-
 329 saturating concentrations, *e.g.* of ADP or oxygen, may not apply to physiological intracellular
 330 conditions, relevant information is obtained in studies of kinetic responses to conditions
 331 intermediate between the LEAK state at zero [ADP] and the OXPHOS-state at saturating
 332 [ADP], or of respiratory capacities in the range between kinetically-saturating [O₂] and anoxia
 333 (Gnaiger 2001).



334
 335 **Fig. 1. The oxidative phosphorylation-pathway, OXPHOS-pathway.** (A) Electron transfer, ET,
 336 coupled to phosphorylation. Multiple convergent ET-pathways are shown from NADH and succinate;
 337 additional arrows indicate electron entry through electron transferring flavoprotein, glycerophosphate
 338 dehydrogenase, dihydro-orotate dehydrogenase, choline dehydrogenase, and sulfide-ubiquinone
 339 oxidoreductase. The branched pathway of oxygen consumption by alternative quinol oxidase (AOX) is

340 indicated by the dotted arrow. The H^+_{\uparrow}/O_2 ratio is the outward proton flux from the matrix space divided
 341 by catabolic O_2 flux in the NADH-pathway. The H^+_{\downarrow}/P_{\gg} ratio is the inward proton flux from the inter-
 342 membrane space divided by the flux of phosphorylation of ADP to ATP. Due to proton leak and slip
 343 these are not fixed stoichiometries. (B) Phosphorylation-pathway catalyzed by the F_1F_0 ATP synthase,
 344 adenine nucleotide translocase, and inorganic phosphate transporter. The H^+_{\downarrow}/P_{\gg} stoichiometry is the
 345 sum of the coupling stoichiometry in the ATP synthase reaction ($-2.7 H^+$ from the intermembrane space,
 346 $2.7 H^+$ to the matrix) and the proton balance in the translocation of ADP^{2-} , ATP^{3-} and P_i^{2-} . See Eqs. 3
 347 and 4 for further explanation. Modified from (A) Lemieux *et al.* (2017) and (B) Gnaiger (2014).
 348



349
 350 **Fig. 2. The proton circuit and coupling in oxidative phosphorylation (OXPHOS).** Oxygen flux, $J_{O_2,k}$,
 351 through the catabolic electron transfer-pathway k is coupled to flux through the phosphorylation-pathway
 352 of ADP to ATP, $J_{P_{\gg}}$, by the proton pumps of the ET-pathway, pushing the outward proton flux, $J_{H^+\uparrow}$, and
 353 generating the output protonmotive force, $F_{H^+\uparrow}$. ATP synthase is coupled to inward proton flux, $J_{H^+\downarrow}$, to
 354 phosphorylate $ADP+P_i$ to ATP, driven by the input protonmotive force, $F_{H^+\downarrow} = -F_{H^+\uparrow}$. $2[H]$ indicates the
 355 reduced hydrogen equivalents of fuel substrates that provide the chemical input force, $F_{O_2,k}$ [kJ/mol O_2],
 356 of the catabolic reaction k with oxygen (Gibbs energy of reaction per mole O_2 consumed in reaction k),
 357 typically in the range of -460 to -480 kJ/mol. The output force is given by the phosphorylation potential
 358 difference (ADP phosphorylated to ATP), $F_{P_{\gg}}$, which varies *in vivo* ranging from about 48 to 62 kJ/mol
 359 under physiological conditions (Gnaiger 1993a). Fluxes, J_B , and forces, F_B , are expressed in either
 360 chemical units, [$mol \cdot s^{-1} \cdot m^{-3}$] and [$J \cdot mol^{-1}$] respectively, or electrical units, [$C \cdot s^{-1} \cdot m^{-3}$] and [$J \cdot C^{-1}$]

361 respectively, per volume, V [m³], of the system. The system defined by the boundaries shown as a full
 362 black line is not a black box, but is analysed as a compartmental system. The negative compartment
 363 (⁻Compartment, enclosed by the dotted line) is the matrix space, separated from the positive
 364 compartment (⁺Compartment) by the mtIM. ADP+P_i and ATP are the substrate- and product-
 365 compartments (scalar ADP and ATP compartments, ^DComp. and ^TComp.), respectively. Chemical
 366 potentials of all substrates and products involved in the scalar reactions are measured in the
 367 ⁺Compartment for calculation of the scalar forces $F_{O_2,k}$ and $F_{P\gg} = -F_{P\ll}$ (**Box 2**). Modified from Gnaiger
 368 (2014).

369

370 **Phosphorylation, P_{gg}**: *Phosphorylation* in the context of OXPHOS is defined as
 371 phosphorylation of ADP to ATP. On the other hand, the term phosphorylation is used generally
 372 in many different contexts, *e.g.* protein phosphorylation. This justifies consideration of a
 373 symbol more discriminating and specific than P as used in the P/O ratio (phosphate to atomic
 374 oxygen ratio; $O = 0.5 O_2$), where P indicates phosphorylation of ADP to ATP or GDP to GTP.
 375 We propose the symbol P_{gg} for the endergonic direction of phosphorylation ADP→ATP, and
 376 likewise the symbol P_{ll} for the corresponding exergonic hydrolysis ATP→ADP (**Fig. 2; Box**
 377 **3**). ATP synthase is the proton pump of the phosphorylation-pathway (**Fig. 1B**). P_{gg} may also
 378 involve substrate-level phosphorylation as part of the tricarboxylic acid cycle (succinyl-CoA
 379 ligase) and phosphorylation of ADP catalyzed by phosphoenolpyruvate carboxykinase,
 380 adenylate kinase, creatine kinase, hexokinase and nucleoside diphosphate kinase (NDPK).
 381 Kinase cycles are involved in intracellular energy transfer and signal transduction for regulation
 382 of energy flux. In isolated mammalian mitochondria ATP production catalyzed by adenylate
 383 kinase, $2ADP \leftrightarrow ATP + AMP$, proceeds without fuel substrates in the presence of ADP
 384 (Komlódi and Tretter 2017). $J_{P\gg}/J_{O_2,k}$ (P_{gg}/O₂) is two times the 'P/O' ratio of classical
 385 bioenergetics. The effective P_{gg}/O₂ ratio is diminished by: (1) the proton leak across the mtIM
 386 from low pH in the ⁺Compartment to high pH in the ⁻Compartment; (2) cycling of other cations;

387 (3) proton slip in the proton pumps when a proton effectively is not pumped; and (4) electron
 388 leak in the univalent reduction of oxygen (O_2 ; dioxygen) to superoxide anion radical ($O_2^{\bullet-}$).

389

390 **Table 1. Coupling states and residual oxygen consumption in mitochondrial**
 391 **preparations in relation to respiration- and phosphorylation-rate, $J_{O_2,k}$ and $J_{P_{\gg}}$,**
 392 **and protonmotive force, $F_{H^+\uparrow}$.** Coupling states are established at kinetically-
 393 saturating concentrations of fuel substrates and O_2 .

State	$J_{O_2,k}$	$J_{P_{\gg}}$	$F_{H^+\uparrow}$	Inducing factors	Limiting factors
LEAK	L ; low proton leak-dependent respiration	0	max.	Proton leak, slip, and cation cycling	$J_{P_{\gg}} = 0$: (1) without ADP, L_N ; (2) max. ATP/ADP ratio, L_T ; or (3) inhibition of the phosphorylation-pathway, L_{Omy}
OXPHOS	P ; high ADP-stimulated respiration	max.	high	Kinetically-saturating [ADP] and $[P_i]$	$J_{P_{\gg}}$ by phosphorylation-pathway; or $J_{O_2,k}$ by ET-capacity
ET	E ; max. noncoupled respiration	0	low	Optimal external uncoupler concentration for max. oxygen flux	$J_{O_2,k}$ by ET-capacity
ROX	R_{ox} ; min. residual O_2 consumption	0	0	$J_{O_2,R_{ox}}$ in non-ET-pathway oxidation reactions	Full inhibition of ET-pathway or absence of fuel substrates

394

395

396
 397 **LEAK-state (Fig. 3):** The
 398 LEAK-state is defined as a state
 399 of mitochondrial respiration when
 400 O₂ flux mainly compensates for
 401 the proton leak in the absence of
 402 ATP synthesis, at kinetically-




Fig. 3. LEAK-state: Phosphorylation is arrested, $J_P = 0$, and oxygen flux, $J_{O_2,L}$, is controlled mainly by the proton leak, which equals $J_{H^+↓}$, at maximum protonmotive force, $F_{H^+↑}$ (See also Fig. 2).

403 saturating concentrations of O₂
 404 and respiratory substrates.
 405 LEAK-respiration is measured to
 406 obtain an indirect estimate of
 407 *intrinsic uncoupling* without addition of any experimental uncoupler: (1) in the absence of
 408 adenylates; (2) after depletion of ADP at maximum ATP/ADP ratio; or (3) after inhibition of
 409 the phosphorylation-pathway by inhibitors of ATP synthase, such as oligomycin, or adenine
 410 nucleotide translocase, such as carboxyatractyloside.

411

412 **Table 2. Distinction of terms related to coupling.**

Term	Respiration	P»/O ₂	Note
Fully coupled	$P - L$	max.	OXPPOS-capacity corrected for LEAK-respiration (Fig. 6)
Well-coupled	P	high	Phosphorylating respiration with a variable intrinsic LEAK component (Fig. 4)
Loosely coupled	up to E	low	Inducibly uncoupled by UCP1 or Ca ²⁺ cycling
Dyscoupled	P	low	Pathologically, toxicologically, environmentally increased uncoupling, mitochondrial dysfunction
Uncoupled and Decoupled	L	0	Non-phosphorylating intrinsic LEAK-respiration without added protonophore (Fig. 3)
Noncoupled	E	0	Non-phosphorylating respiration stimulated to maximum flux at optimum exogenous uncoupler concentration (Fig. 5)

413

414 **Proton leak:** Proton leak is the *uncoupled* process in which protons are translocated
415 across the mtIM in the dissipative direction of the downhill protonmotive force without
416 coupling to phosphorylation (**Fig. 3**). The proton leak flux depends non-linearly on the
417 protonmotive force (Garlid *et al.* 1989; Divakaruni and Brand 2011), is a property of the mtIM,
418 may be enhanced due to possible contaminations by free fatty acids, and is physiologically
419 controlled. In particular, inducible uncoupling mediated by uncoupling protein 1 (UCP1) is
420 physiologically controlled, *e.g.*, in brown adipose tissue. UCP1 is a proton channel of the mtIM
421 facilitating the conductance of protons across the mtIM (Klingenberg 2017). As a consequence
422 of this effective short-circuit, the protonmotive force diminishes, resulting in stimulation of
423 electron transfer to oxygen and heat dissipation without phosphorylation of ADP.
424 Mitochondrial injuries may lead to *dyscoupling* as a pathological or toxicological cause of
425 *uncoupled* respiration, *e.g.*, as a consequence of opening the permeability transition pore.
426 Dyscoupled respiration is distinguished from the experimentally induced *noncoupled*
427 respiration in the ET-state. Under physiological conditions, the proton leak is the dominant
428 contributor to the overall leak current (Dufour *et al.* 1996).


429 **Proton slip:** Proton slip is the *decoupled* process in which protons are only partially
430 translocated by a proton pump of the ET-pathways and slip back to the original compartment
431 (Dufour *et al.* 1996). Proton slip can also happen in association with the ATP-synthase, in which
432 case the proton slips downhill across the membrane to the matrix without contributing to ATP
433 synthesis. In each case, proton slip is a property of the proton pump and increases with the
434 turnover rate of the pump.

435 **Cation cycling:** Proton leak is a leak current of protons. There can be other cation
436 contributors to leak current including calcium and probably magnesium. Calcium current is
437 balanced by mitochondrial Na/Ca exchange, which is balanced by Na/H exchange or K/H
438 exchange. This is another effective uncoupling mechanism different from proton leak and slip.

439 Small differences of terms, *e.g.*, uncoupled, noncoupled, are easily overlooked and may
 440 be erroneously perceived as identical. Even with an attempt at rigorous definition, the common
 441 use of such terms may remain vague (Table 2).

442 **OXPHOS-state (Fig. 4):**

443 The OXPHOS-state is defined as
 444 the respiratory state with
 445 kinetically-saturating
 446 concentrations of O₂, respiratory
 447 and phosphorylation substrates,
 448 and absence of exogenous
 449 uncoupler, which provides an
 450 estimate of the maximal
 451 respiratory capacity in the



452 **Fig. 4. OXPHOS-state:** Phosphorylation, $J_{P\gg}$, is stimulated
 453 by kinetically-saturating [ADP] and inorganic phosphate,
 454 [Pi], and is supported by a high protonmotive force, $F_{H^+\uparrow}$. O₂
 455 flux, $J_{O_2,P}$, is well-coupled at a $P\gg/O_2$ ratio of $J_{P\gg,P}/J_{O_2,P}$ (See
 456 also Fig. 2).


457 OXPHOS-state for any given ET-pathway state. Respiratory capacities at kinetically-saturating
 458 substrate concentrations provide reference values or upper limits of performance, aiming at the
 459 generation of data sets for comparative purposes. Any effects of substrate kinetics are thus
 460 separated from reporting actual mitochondrial capacity for oxidation during well-coupled
 461 respiration, against which physiological activities can be evaluated.

462 As discussed previously, 0.2 mM ADP does not fully saturate flux in isolated
 463 mitochondria (Gnaiger 2001; Puchowicz *et al.* 2004); greater ADP concentration is required,
 464 particularly in permeabilized muscle fibres and cardiomyocytes, to overcome limitations by
 intracellular diffusion and by the reduced conductance of the mitochondrial outer membrane,
 mtOM (Jepihhina *et al.* 2011, Illaste *et al.* 2012, Simson *et al.* 2016) either through interaction
 with tubulin (Rostovtseva *et al.* 2008) or other intracellular structures (Birkedal *et al.* 2014). In
 permeabilized muscle fibre bundles of high respiratory capacity, the apparent K_m for ADP
 increases up to 0.5 mM (Saks *et al.* 1998), indicating that >90% saturation is reached only at

465 >5 mM ADP. Similar ADP concentrations are also required for accurate determination of
 466 OXPHOS-capacity in human clinical cancer samples and permeabilized cells (Klepinin *et al.*
 467 2016; Koit *et al.* 2017). Whereas 2.5 to 5 mM ADP is sufficient to obtain the actual OXPHOS-
 468 capacity in many types of permeabilized cell and tissue preparations, experimental validation
 469 is required in each specific case.

470 Electron transfer-state

471 (Fig. 5): The ET-state is defined
 472 as the *noncoupled* state with
 473 kinetically-saturating
 474 concentrations of O₂, respiratory
 475 substrate and optimum
 476 exogenous uncoupler
 477 concentration for maximum O₂
 478 flux, as an estimate of oxidative



479 **Fig. 5. ET-state:** Noncoupled respiration, $J_{O_2,E}$, is maximum
 480 at optimum exogenous uncoupler concentration and
 481 phosphorylation is zero, $J_{P_{\gg}} = 0$ (See also Fig. 2).

479 ET-capacity. Inhibition of respiration is observed at higher than optimum uncoupler
 480 concentrations. As a consequence of the nearly collapsed protonmotive force, the driving force
 481 is insufficient for phosphorylation and $J_{P_{\gg}} = 0$.

482 Besides the three fundamental coupling states of mitochondrial preparations, the
 483 following respiratory state also is relevant to assess respiratory function:

484 **ROX:** Residual oxygen consumption (ROX) is defined as O₂ consumption due to
 485 oxidative side reactions remaining after inhibition of ET with rotenone, malonic acid and
 486 antimycin A. Cyanide and azide not only inhibit CIV but several peroxidases which might be
 487 involved in ROX. ROX is not a coupling state but represents a baseline that is used to correct
 488 mitochondrial respiration in defined coupling states. ROX is not necessarily equivalent to non-
 489 mitochondrial respiration, considering oxygen-consuming reactions in mitochondria not related
 490 to ET, such as oxygen consumption in reactions catalyzed by monoamine oxidases (type A and

491 B), monooxygenases (cytochrome P450 monooxygenases), dioxygenase (sulfur dioxygenase
 492 and trimethyllysine dioxygenase), several hydroxylases, and more. Mitochondrial preparations,
 493 especially those obtained from liver, are contaminated by peroxisomes. This fact makes the
 494 exact determination of mitochondrial oxygen consumption and mitochondria-associated
 495 generation of reactive oxygen species complicated (Schönfeld *et al.* 2009). The dependence of
 496 ROX-linked oxygen consumption needs to be studied in detail with respect to non-ET enzyme
 497 activities, availability of specific substrates, oxygen concentration, and electron leakage leading
 498 to the formation of reactive oxygen species.

499


500 2.2. Coupling states and respiratory rates

501 It is important to distinguish metabolic pathways from metabolic states and the
 502 corresponding metabolic rates; for example: ET-pathways (**Fig. 6**), ET-state (**Fig. 5**), and ET-
 503 capacity, E , respectively (**Table 1**). The protonmotive force is *high* in the OXPHOS-state when
 504 it drives phosphorylation, *maximum* in the LEAK-state of coupled mitochondria, driven by
 505 LEAK-respiration at a minimum back flux of protons to the matrix side, and *very low* in the
 506 ET-state when uncouplers short-circuit the proton cycle (**Table 1**).

507

508 **Fig. 6. Four-compartment model**
 509 **of oxidative phosphorylation.**

510 Respiratory states (ET, OXPHOS,
 511 LEAK) and corresponding rates (E ,
 512 P , L) are connected by the
 513 protonmotive force, F_{H^+} . Electron
 514 transfer-capacity, E , is partitioned



515 into (1) dissipative LEAK-respiration, L , when the capacity to perform work is irreversibly lost, (2) net
 516 OXPHOS-capacity, $P-L$, with partial conservation of the capacity to perform work, and (3) the excess
 517 capacity, $E-P$. Modified from Gnaiger (2014).

518

519 The three coupling states, ET, LEAK and OXPHOS, are presented in a schematic context
520 with the corresponding respiratory rates, abbreviated as E , L and P , respectively (Fig. 6). This
521 clarifies that E may exceed or be equal to P , but E cannot theoretically be lower than P . $E < P$
522 must be discounted as an artefact, which may be caused experimentally by: (1) loss of oxidative
523 capacity during the time course of the respirometric assay, since E is measured subsequently to
524 P ; (2) using insufficient uncoupler concentrations; (3) using high uncoupler concentrations which
525 inhibit ET (Gnaiger 2008); (4) high oligomycin concentrations applied for measurement of L
526 before titrations of uncoupler, when oligomycin exerts an inhibitory effect on E . On the other
527 hand, the excess ET-capacity is overestimated if non-saturating $[P_i]$ or $[ADP]$ are used (see
528 State 3 in the next section).

529 $E > P$ is observed in many types of mitochondria, varying between species, tissues and
530 cell types. It is the excess ET-capacity pushing the phosphorylation-flux (Fig. 1B) to the limit
531 of its *capacity of utilizing* the protonmotive force. Within any type of mitochondria, the
532 magnitude of $E > P$ depends on (1) the pathway control state with single or multiple electron
533 input into the Q-junction and involvement of three or fewer coupling sites determining the
534 $H^+ \uparrow / O_2$ coupling stoichiometry (Fig. 1A); and (2) the *biochemical coupling efficiency* expressed
535 as $(E-L)/E$, since an increase of L causes P to increase towards the limit of E . The *excess* $E-P$
536 capacity, $E-P$, therefore, provides a sensitive diagnostic indicator of specific injuries of the
537 phosphorylation-pathway, under conditions when E remains constant but P declines relative to
538 controls (Fig. 6). Substrate cocktails supporting simultaneous convergent electron transfer to
539 the Q-junction for reconstitution of tricarboxylic acid cycle (TCA cycle) function establish
540 pathway control states with high ET-capacity, and consequently increase the sensitivity of the
541 $E-P$ assay.

542 When subtracting L from P , the dissipative LEAK component in the OXPHOS-state may
543 be overestimated. This can be avoided by measuring LEAK-respiration in a state when the
544 protonmotive force is adjusted to its slightly lower value in the OXPHOS-state, *e.g.*, by titration

545 of an ET inhibitor. Any turnover-dependent components of proton leak and slip, however, are
 546 underestimated under these conditions (Garlid *et al.* 1993). In general, it is inappropriate to use
 547 the term *ATP production* or *ATP turnover* for the difference of oxygen consumption measured
 548 in states *P* and *L*. The difference *P-L* is the upper limit of the part of OXPHOS-capacity that is
 549 freely available for ATP production (corrected for LEAK-respiration) and is fully coupled to
 550 phosphorylation with a maximum mechanistic stoichiometry (**Fig. 6**).

551

552 2.3. Classical terminology for isolated mitochondria

553 *‘When a code is familiar enough, it ceases appearing like a code; one forgets that*
 554 *there is a decoding mechanism. The message is identical with its meaning’*
 555 (Hofstadter 1979).

556 Chance and Williams (1955; 1956) introduced five classical states of mitochondrial respiration
 557 and cytochrome redox states. **Table 3** shows a protocol with isolated mitochondria in a closed
 558 respirometric chamber, defining a sequence of respiratory states.

559 **Table 3. Metabolic states of mitochondria (Chance and**
 560 **Williams, 1956; Table V).**
 561

State	[O ₂]	ADP level	Substrate level	Respiration rate	Rate-limiting substance
1	>0	low	Low	slow	ADP
2	>0	high	~0	slow	substrate
3	>0	high	High	fast	respiratory chain
4	>0	low	High	slow	ADP
5	0	high	High	0	oxygen

562

563 **State 1** is obtained after addition of isolated mitochondria to air-saturated
 564 isoosmotic/isotonic respiration medium containing inorganic phosphate, but no fuel substrates
 565 and no adenylates, *i.e.*, AMP, ADP, ATP.

566 **State 2** is induced by addition of a high concentration of ADP (typically 100 to 300 μ M),
 567 which stimulates respiration transiently on the basis of endogenous fuel substrates and

568 phosphorylates only a small portion of the added ADP. State 2 is then obtained at a low
569 respiratory activity limited by zero endogenous fuel substrate availability (**Table 3**). If addition
570 of specific inhibitors of respiratory complexes, such as rotenone, does not cause a further
571 decline of oxygen consumption, State 2 is equivalent to residual oxygen consumption (See
572 below). If inhibition is observed, undefined endogenous fuel substrates are a confounding factor
573 of pathway control by externally added substrates and inhibitors. In contrast to the original
574 protocol, an alternative sequence of titration steps is frequently applied, in which the alternative
575 State 2 has an entirely different meaning, when this second state is induced by addition of fuel
576 substrate without ADP (LEAK-state; in contrast to State 2 defined in **Table 2** as a ROX state),
577 followed by addition of ADP.

578 **State 3** is the state stimulated by addition of fuel substrates while the ADP concentration
579 is still high (**Table 3**) and supports coupled energy transformation through oxidative
580 phosphorylation. 'High ADP' is a concentration of ADP specifically selected to allow the
581 measurement of State 3 to State 4 transitions of isolated mitochondria in a closed respirometric
582 chamber. Repeated ADP titration re-establishes State 3 at 'high ADP'. Starting at oxygen
583 concentrations near air-saturation (ca. 200 μM O_2 at sea level and 37 $^\circ\text{C}$), the total ADP
584 concentration added must be low enough (typically 100 to 300 μM) to allow phosphorylation
585 to ATP at a coupled oxygen consumption that does not lead to oxygen depletion during the
586 transition to State 4. In contrast, kinetically-saturating ADP concentrations usually are an order
587 of magnitude higher than 'high ADP', e.g. 2.5 mM in isolated mitochondria. The abbreviation
588 State 3u is frequently used in bioenergetics, to indicate the state of respiration after titration of
589 an uncoupler, without sufficient emphasis on the fundamental difference between OXPHOS-
590 capacity (*well-coupled* with an *endogenous* uncoupled component) and ET-capacity
591 (*noncoupled*).

592 **State 4** is a LEAK-state that is obtained only if the mitochondrial preparation is intact
593 and well-coupled. Depletion of ADP by phosphorylation to ATP leads to a decline in oxygen

594 consumption in the transition from State 3 to State 4. Under these conditions, a maximum
 595 protonmotive force and high ATP/ADP ratio are maintained, and the P_{\gg}/O_2 ratio can be
 596 calculated. State 4 respiration, L_T (**Table 1**), reflects intrinsic proton leak and intrinsic ATP
 597 hydrolysis activity. Oxygen consumption in State 4 is an overestimation of LEAK-respiration
 598 if the contaminating ATP hydrolysis activity recycles some ATP to ADP, $J_{P\ll}$, which stimulates
 599 respiration coupled to phosphorylation, $J_{P\gg} > 0$. This can be tested by inhibition of the
 600 phosphorylation-pathway using oligomycin, ensuring that $J_{P\gg} = 0$ (State 4o). Alternatively,
 601 sequential ADP titrations re-establish State 3, followed by State 3 to State 4 transitions while
 602 sufficient oxygen is available. However, anoxia may be reached before exhaustion of ADP
 603 (State 5).

604 **State 5** is the state after exhaustion of oxygen in a closed respirometric chamber.
 605 Diffusion of oxygen from the surroundings into the aqueous solution may be a confounding
 606 factor preventing complete anoxia (Gnaiger 2001). Chance and Williams (1955) provide an
 607 alternative definition of State 5, which gives it the meaning of ROX: ‘State 5 may be obtained
 608 by antimycin A treatment or by anaerobiosis’.

609 In **Table 3**, only States 3 and 4 (and ‘State 2’ in the alternative protocol without ADP;
 610 not included in the table) are coupling control states, with the restriction that O_2 flux in State 3
 611 may be limited kinetically by non-saturating ADP concentrations (**Table 1**).

612

613 **3. The protonmotive force and proton flux**

614 *3.1. Electric and chemical partial forces versus electrical and chemical units*

615 The protonmotive force across the mtIM (Mitchell 1961; Mitchell and Moyle 1967) was
 616 introduced most beautifully in the *Grey Book 1966* (see Mitchell 2011),

$$617 \quad \Delta p = \Delta \Psi + \Delta \mu_{H^+}/F \quad (\text{Eq. 1})$$

618 The protonmotive force, Δp , consists of two partial forces: (1) The electrical part, $\Delta \Psi$, is the
 619 difference of charge (electric potential difference), is not specific for H^+ , and can, therefore, be

620 measured by the distribution of other cations between the positive and negative compartment
 621 (**Fig. 2**). (2) The chemical part, $\Delta\mu_{H^+}$, is the chemical potential difference in H^+ , is proportional
 622 to the pH difference, and incorporates the Faraday constant (**Table 4**).

623
 624 **Table 4. Protonmotive force and flux matrix.** Columns: The protonmotive force is
 625 the sum of *partial isomorphic forces*, F_{el} and $F_{H^+,d}$. Rows: Electrical and chemical units
 626 (isomorphic format e and n). The Faraday constant, F , converts protonmotive force
 627 and flux from *format e* to n . In contrast to force (state), the conjugated flux (rate) cannot
 628 be partitioned.
 629

State	Force		electric	+ chem.	Unit	Notes
Protonmotive force, e	Δp	=	$\Delta\Psi$	+ $\Delta\mu_{H^+}/F$	$J\cdot C^{-1}$	$1e$
Chemiosmotic potential, n	$\Delta\tilde{\mu}_{H^+}$	=	$\Delta\Psi\cdot F$	+ $\Delta\mu_{H^+}$	$J\cdot mol^{-1}$	$1n$
State	Isomorphic force		e	+ H^+_d		
Electric charge, e	$F_{H^+/e}$	=	$F_{el/e}$	+ $F_{H^+,d/e}$	$J\cdot C^{-1}$	$2e$
Amount of substance, n	$F_{H^+/n}$	=	$F_{el/n}$	+ $F_{H^+,d/n}$	$J\cdot mol^{-1}$	$2n$
Rate	Isomorphic flux		e	or N		
Electric charge, e	$J_{H^+/e}$		$J_{H^+/e}$		$C\cdot s^{-1}\cdot m^{-3}$	$3e$
Amount of substance, n	$J_{H^+/n}$			$J_{H^+/n}$	$mol\cdot s^{-1}\cdot m^{-3}$	$3n$

630
 631 1: The Faraday constant, F , is the product of elementary charge ($e = 1.602177\cdot 10^{-19}\cdot C$) and the
 632 Avogadro (Loschmidt) constant ($N_A = 6.022136\cdot 10^{23}\cdot mol^{-1}$), $F = eN_A = 96,485.3 C\cdot mol^{-1}$, *i.e.* the
 633 conversion factor between electrical and chemical units. $\Delta\tilde{\mu}_{H^+}$ is the chemiosmotic potential
 634 difference. $1e$ and $1n$ are the classical representations of $2e$ and $2n$.
 635 2: F_{H^+} is the protonmotive force expressed in either isomorphic format e or n . $F_{el/e} \equiv \Delta\Psi$ is the partial
 636 protonmotive force (e) acting generally on charged motive molecules (*i.e.* ions that are displaceable
 637 across the mtIM). In contrast, $F_{H^+,d/n} \equiv \Delta\mu_{H^+}$ is the partial protonmotive force specific for proton
 638 displacement (H^+_d). The sign of the force is negative for exergonic transformations in which exergy
 639 is lost or dissipated ($F_{H^+,in}$), and positive for endergonic transformations which conserve exergy in a
 640 coupled exergonic process, $F_{H^+\uparrow} = -F_{H^+\downarrow}$ (**Box 3**).

641 3: The sign of the flux, J_{H^+} , depends on the definition of the compartmental direction of the translocation.
 642 For the outward direction, $J_{H^+\uparrow}$, flux is positive since the direction involves formation of H^+ in the
 643 $^+$ Compartment ($H^+\uparrow$ is added, $v_{H^+\uparrow} = 1$; and $H^+\downarrow$ is removed, $v_{H^+\downarrow} = -1$). Equally, $J_{H^+\downarrow}$ is positive since
 644 the direction involves formation of H^+ in the $^-$ Compartment ($H^+\downarrow$ is added, $v_{H^+\downarrow} = 1$; and $H^+\uparrow$ is removed,
 645 $v_{H^+\uparrow} = -1$; **Fig. 2**). The product of flux and force is volume-specific power [$J \cdot s^{-1} \cdot m^{-3} = W \cdot m^{-3}$]: $P_{V,H^+} =$
 646 $J_{H^+\uparrow/e} \cdot F_{H^+\uparrow/e} = J_{H^+\uparrow/n} \cdot F_{H^+\uparrow/n}$.

647
 648 **Faraday constant**, $F = eN_A$ [C/mol] (**Table 4**), enables the conversion between
 649 protonmotive force, $F_{H^+/e} \equiv \Delta p$ [J/C], expressed per *motive charge*, e [C], and protonmotive
 650 force or electrochemical potential difference, $F_{H^+/n} \equiv \Delta \tilde{\mu}_{H^+} = \Delta p \cdot F$ [J/mol], expressed per
 651 *motive amount of protons*, n [mol]. Proton charge, e , and amount of substance, n , define the
 652 units for the isomorphic formats. Taken together, F is the conversion factor for expressing
 653 protonmotive force and flux in either isomorphic format e or n (Eq. 2; **Table 4**, Notes 1 and 2),

$$654 \quad F_{H^+/n} = F_{H^+/e} \cdot eN_A \quad (\text{Eq. 2.1})$$

$$655 \quad J_{H^+/n} = J_{H^+/e} / (eN_A) \quad (\text{Eq. 2.2})$$

656 In each format, the protonmotive force is expressed as the sum of two partial forces. The
 657 complex symbols in Eq. 1 can be explained and visualized more explicitly by *partial*
 658 *isomorphic forces* as the components of the protonmotive force:

659 **Electrical part of the protonmotive force:** (1) Isomorph e : $F_{el/e} \equiv \Delta \Psi$ is the electrical
 660 part of the protonmotive force expressed in units joule per coulomb, *i.e.* volt [$V = J/C$]. $F_{el/e}$ is
 661 defined as partial Gibbs energy change per *motive elementary charge*, e [C], not specific for
 662 proton charge (**Table 4**, Note 2e). (2) Isomorph n : $F_{el/n} \equiv \Delta \Psi \cdot F$ is the electric force expressed
 663 in units joule per mole [J/mol], defined as partial Gibbs energy change per *motive amount of*
 664 *charge*, n [mol], not specific for proton charge (**Table 4**, Note 2n).

665 **Chemical part of the protonmotive force:** (1) Isomorph n : $F_{H^+,d/n} \equiv \Delta \mu_{H^+}$ is the chemical
 666 part (diffusion, displacement of H^+) of the protonmotive force expressed in units joule per mole
 667 [J/mol]. $F_{H^+,d/n}$ is defined as partial Gibbs energy change per *motive amount of protons*, n [mol]

668 (Table 4, Note 2n). (2) Isomorph e : $F_{H^+,d/e} \equiv \Delta\mu_{H^+}/F$ is the chemical force expressed in units
 669 joule per coulomb [V], defined as partial Gibbs energy change per *motive amount of protons*
 670 *expressed in units of electric charge, e [C]*, but specific for proton charge (Table 4, Note 2e).

671 Protonmotive means that there is a potential for the movement of protons, and force is a
 672 measure of the potential for motion. Motion is relative and not absolute (Principle of Galilean
 673 Relativity); likewise there is no absolute potential, but (isomorphic) forces are potential
 674 differences. An electric partial force expressed in the format of electric charge, $F_{el\uparrow/e}$, of 0.2 V
 675 (Table 5, Note 5e) can be expressed equivalently in the format of amount, $F_{el\uparrow/n}$, of $19 \text{ kJ}\cdot\text{mol}^{-1}$
 676 $\text{H}^+\uparrow$ (Note 5n). For a ΔpH of 1 unit, the chemical partial force in the format of amount, $F_{H^+\uparrow,d/n}$,
 677 changes by $5.9 \text{ kJ}\cdot\text{mol}^{-1}$ (Table 5, Note 6n) and chemical force in the format of charge $F_{H^+\uparrow,d/e}$
 678 changes by 0.06 V (Note 6e). Considering a driving force of $-470 \text{ kJ}\cdot\text{mol}^{-1}$ O_2 for oxidation, the
 679 thermodynamic limit of the $\text{H}^+\uparrow/\text{O}_2$ ratio is reached at a value of $470/19 = 24$, compared to a
 680 mechanistic stoichiometry of 20 (Fig. 1).

681

682 3.2. Definitions

683 **Control and regulation:** The terms metabolic *control* and *regulation* are frequently used
 684 synonymously, but are distinguished in metabolic control analysis: ‘We could understand the
 685 regulation as the mechanism that occurs when a system maintains some variable constant over
 686 time, in spite of fluctuations in external conditions (homeostasis of the internal state). On the
 687 other hand, metabolic control is the power to change the state of the metabolism in response to
 688 an external signal’ (Fell 1997). Respiratory control may be induced by experimental control
 689 signals that *exert* an influence on: (1) ATP demand and ADP phosphorylation-rate; (2) fuel
 690 substrate composition, pathway competition; (3) available amounts of substrates and oxygen,
 691 *e.g.*, starvation and hypoxia; (3) the protonmotive force, redox states, flux-force relationships,
 692 coupling and efficiency; (4) Ca^{2+} and other ions including H^+ ; (5) inhibitors, *e.g.*, nitric oxide
 693 or intermediary metabolites, such as oxaloacetate; (6) signalling pathways and regulatory

694 proteins, *e.g.* insulin resistance, transcription factor HIF-1 or inhibitory factor 1. *Mechanisms*
695 of respiratory control and regulation include adjustments of (1) enzyme activities by allosteric
696 mechanisms and phosphorylation, (2) enzyme content, concentrations of cofactors and
697 conserved moieties (such as adenylates, nicotinamide adenine dinucleotide [NAD⁺/NADH],
698 coenzyme Q, cytochrome *c*); (3) metabolic channeling by supercomplexes; and (4)
699 mitochondrial density (enzyme concentrations and membrane area) and morphology (cristae
700 folding, fission and fusion). (5) Mitochondria are targeted directly by hormones, thereby
701 affecting their energy metabolism (Lee *et al.* 2013; Gerö and Szabo 2016; Price and Dai 2016;
702 Moreno *et al.* 2017). Evolutionary or acquired differences in the genetic and epigenetic basis
703 of mitochondrial function (or dysfunction) between subjects and gene therapy; age; gender,
704 biological sex, and hormone concentrations; life style including exercise and nutrition; and
705 environmental issues including thermal, atmospheric, toxicological and pharmacological
706 factors, exert an influence on all control mechanisms listed above (for reviews, see Brown 1992;
707 Gnaiger 1993a, 2009; 2014; Paradies *et al.* 2014; Morrow *et al.* 2017).

708 **Respiratory control and response:** Lack of control by a metabolic pathway, *e.g.*
709 phosphorylation-pathway, does mean that there will be no response to a variable activating it,
710 *e.g.* [ADP]. However, the reverse is not true as the absence of a response to [ADP] does not
711 exclude the phosphorylation-pathway from having some degree of control. The degree of
712 control of a component of the OXPHOS-pathway on an output variable, such as oxygen flux,
713 will in general be different from the degree of control on other outputs, such as phosphorylation-
714 flux or proton leak flux (**Box 2**). As such, it is necessary to be specific as to which input and
715 output are under consideration (Fell 1997). Therefore, the term respiratory control is elaborated
716 in more detail in the following section.

717 **Respiratory coupling control:** Respiratory control refers to the ability of mitochondria
718 to adjust oxygen consumption in response to external control signals by engaging various
719 mechanisms of control and regulation. Respiratory control is monitored in a mitochondrial

720 preparation under conditions defined as respiratory states. When phosphorylation of ADP to
721 ATP is stimulated or depressed, an increase or decrease is observed in electron flux linked to
722 oxygen consumption in respiratory coupling states of intact mitochondria ('controlled states' in
723 the classical terminology of bioenergetics). Alternatively, coupling of electron transfer with
724 phosphorylation is disengaged by disruption of the integrity of the mtIM or by uncouplers,
725 functioning like a clutch in a mechanical system. The corresponding coupling control state is
726 characterized by high levels of oxygen consumption without control by phosphorylation
727 ('uncontrolled state'). Energetic coupling is defined in **Box 4**. Loss of coupling lowers the
728 efficiency by intrinsic uncoupling and decoupling, or pathological dyscoupling. Such
729 generalized uncoupling is different from switching to mitochondrial pathways that involve
730 fewer than three proton pumps ('coupling sites': Complexes CI, CIII and CIV), bypassing CI
731 through multiple electron entries into the Q-junction (**Fig. 1**). A bypass of CIII and CIV is
732 provided by alternative oxidases, which reduce oxygen without proton translocation.
733 Reprogramming of mitochondrial pathways may be considered as a switch of gears (changing
734 the stoichiometry) rather than uncoupling (loosening the stoichiometry).

735 **Pathway control states** are obtained in mitochondrial preparations by depletion of
736 endogenous substrates and addition to the mitochondrial respiration medium of fuel substrates
737 (CHNO) and specific inhibitors, activating selected mitochondrial pathways (**Fig. 1**). Coupling
738 control states and pathway control states are complementary, since mitochondrial preparations
739 depend on an exogenous supply of pathway-specific fuel substrates and oxygen (Gnaiger 2014).

740

741 **Box 2: Metabolic fluxes and flows: vectorial and scalar**

742 In mitochondrial electron transfer (**Fig. 1**), vectorial transmembrane proton flux is coupled
743 through the proton pumps CI, CIII and CIV to the catabolic flux of scalar reactions, collectively
744 measured as oxygen flux. In **Fig. 2**, the scalar catabolic reaction, k , of oxygen consumption,

745 $J_{O_2,k}$ [$\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}$], is expressed as oxygen flux per volume, V [m^3], of the instrumental chamber
746 (the system).

747 Fluxes are *vectors*, if they have *spatial* direction in addition to magnitude. A vector flux
748 (surface-density of flow) is expressed per unit cross-sectional area, A [m^2], perpendicular to the
749 direction of flux. If *flows*, I , are defined as extensive quantities of the *system*, as vector or scalar
750 flow, \mathbf{I} or I [$\text{mol}\cdot\text{s}^{-1}$], respectively, then the corresponding vector and scalar *fluxes*, \mathbf{J} , are
751 obtained as $\mathbf{J} = \mathbf{I}\cdot A^{-1}$ [$\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-2}$] and $J = I\cdot V^{-1}$ [$\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}$], respectively, expressing flux as an
752 area-specific vector or volume-specific scalar quantity.

753 Vectorial transmembrane proton fluxes, $J_{H^+\uparrow}$ and $J_{H^+\downarrow}$, are analyzed in a heterogenous
754 compartmental system as a quantity with *directional* but not *spatial* information. Translocation
755 of protons across the mtIM has a defined direction, either from the negative compartment
756 (matrix space; negative or $\bar{\text{Compartment}}$) to the positive compartment (inter-membrane space;
757 positive or $^+\text{Compartment}$) or *vice versa* (**Fig. 2**). The arrows defining the direction of the
758 translocation between the two compartments may point upwards or downwards, right or left,
759 without any implication that these are actual directions in space. The $^+\text{Compartment}$ is neither
760 above nor below the $\bar{\text{Compartment}}$ in a spatial sense, but can be visualized arbitrarily in a figure
761 in the upper position (**Fig. 2**). In general, the *compartmental direction* of vectorial translocation
762 from the $\bar{\text{Compartment}}$ to the $^+\text{Compartment}$ is defined by assigning the initial and final state
763 as *ergodynamic compartments*, $H^+\downarrow \rightarrow H^+\uparrow$ or $0 = -H^+\downarrow + H^+\uparrow$, related to work (erg = work) that
764 must be performed to lift the proton from a lower to a higher electrochemical potential or from
765 the lower to the higher ergodynamic compartment (Gnaiger 1993b).

766 In direct analogy to *vectorial* translocation, the direction of a *scalar* chemical reaction, A
767 $\rightarrow B$ or $0 = -A+B$, is defined by assigning substrates and products, A and B , as ergodynamic
768 compartments. O_2 is defined as a substrate in respiratory O_2 consumption, which together with
769 the fuel substrates comprises the substrate compartment of the catabolic reaction (**Fig. 2**).
770 Volume-specific scalar O_2 flux is coupled (**Box 4**) to vectorial translocation. In order to

771 establish a quantitative relation between the coupled fluxes, both $J_{O_2,k}$ and $J_{H^+\uparrow}$ must be
 772 expressed in identical isomorphic units, $[\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}]$ or $[\text{C}\cdot\text{s}^{-1}\cdot\text{m}^{-3}]$, yielding the $H^+\uparrow/O_2$ ratio
 773 (**Fig. 1**). The *vectorial* proton flux in compartmental translocation has *compartmental direction*,
 774 distinguished from a *vector* flux with *spatial direction*. Likewise, the corresponding
 775 protonmotive force is defined as an electrochemical potential *difference* between two
 776 compartments, in contrast to a *gradient* across the membrane or a vector force with defined
 777 spatial direction.

778

779 **The steady-state:** Mitochondria represent a thermodynamically open system functioning
 780 as a biochemical transformation system in non-equilibrium states. State variables (protonmotive
 781 force; redox states) and metabolic fluxes (*rates*) are measured in defined mitochondrial
 782 respiratory *states*. Strictly, steady states can be obtained only in open systems, in which changes
 783 due to *internal* transformations, *e.g.*, O_2 consumption, are instantaneously compensated for by
 784 *external* fluxes *e.g.*, O_2 supply, such that oxygen concentration does not change in the system
 785 (Gnaiger 1993b). Mitochondrial respiratory states monitored in closed systems satisfy the
 786 criteria of pseudo-steady states for limited periods of time, when changes in the system
 787 (concentrations of O_2 , fuel substrates, ADP, P_i , H^+) do not exert significant effects on metabolic
 788 fluxes (respiration, phosphorylation). Such pseudo-steady states require respiratory media with
 789 sufficient buffering capacity and kinetically-saturating concentrations of substrates to be
 790 maintained, and thus depend on the kinetics of the processes under investigation. Proton
 791 turnover, $J_{\infty H^+}$, and ATP turnover, $J_{\infty P}$, proceed in the steady-state at constant $F_{H^+\uparrow}$, when $J_{H^+\infty}$
 792 $= J_{H^+\uparrow} = J_{H^+\downarrow}$, and at constant $F_{P\gg}$, when $J_{P\infty} = J_{P\gg} = J_{P\ll}$ (**Fig. 2**).

793

794 **Box 3: Endergonic and exergonic transformations, exergy and dissipation**

795 A chemical reaction, or any transformation, is exergonic if the Gibbs energy change (exergy)
 796 of the reaction is negative at constant temperature and pressure. The sum of Gibbs energy

797 changes of all internal transformations in a system can only be negative, *i.e.* exergy is
798 irreversibly dissipated. Endergonic reactions are characterized by positive Gibbs energies of
799 reaction and cannot proceed spontaneously in the forward direction as defined. For instance,
800 the endergonic reaction $P \gg$ is coupled to exergonic catabolic reactions, such that the total Gibbs
801 energy change is negative, *i.e.* exergy must be dissipated for the reaction to proceed (**Fig. 2**).

802 In contrast, energy cannot be lost or produced in any internal process, which is the key
803 message of the first law of thermodynamics. Thus mitochondria are the sites of energy
804 transformation but not energy production. Open and closed systems can gain energy and exergy
805 only by external fluxes, *i.e.* uptake from the environment. Exergy is the potential to perform
806 work. In the framework of flux-force relationships (**Box 4**), the *partial* derivative of Gibbs
807 energy per advancement of a transformation is an isomorphic force, F_{tr} (**Table 5**, Note 2). In
808 other words, force is equal to exergy/motive unit (in integral form, this definition takes care of
809 non-isothermal processes). This formal generalization represents an appreciation of the
810 conceptual beauty of Peter Mitchell's innovation of the protonmotive force against the
811 background of the established paradigm of the electromotive force (emf) defined at the limit of
812 zero current (Cohen *et al.* 2008).

813

814 *3.3. Forces and fluxes in physics and irreversible thermodynamics*

815 According to its definition in physics, a potential difference and as such the
816 *protonmotive force*, Δp , is not a force *per se* (Cohen *et al.* 2008). The fundamental forces of
817 physics are distinguished from *motive forces* of statistical and irreversible thermodynamics.
818 Complementary to the attempt towards unification of fundamental forces defined in physics,
819 the concepts of Nobel laureates Lars Onsager, Erwin Schrödinger, Ilya Prigogine and Peter
820 Mitchell (even if expressed in apparently unrelated terms) unite the diversity of *generalized* or
821 'isomorphic' *flux-force* relationships, the product of which links to the dissipation function and
822 Second Law of thermodynamics (Schrödinger 1944; Prigogine 1967). A *motive force* is the

823 derivative of potentially available or ‘free’ energy (exergy) per isomorphic *motive* unit (**Box 3**).
 824 Perhaps the first account of a *motive force* in energy transformation can be traced back to the
 825 Peripatetic school around 300 BC in the context of moving a lever, up to Newton’s motive force
 826 proportional to the alteration of motion (Coopersmith 2010). As a generalization, isomorphic
 827 motive forces are considered as *entropic forces* in physics (Wang 2010).

828

829 **Table 5. Power, exergy, force, flux, and advancement.**

830

Expression	Symbol	Definition	Unit	Notes
Power, volume-specific	$P_{V,tr}$	$P_{V,tr} = J_{tr} \cdot F_{tr} = d_{tr}G \cdot dt^{-1}$	$W \cdot m^{-3} = J \cdot s^{-1} \cdot m^{-3}$	1
Force, isomorphic	F_{tr}	$F_{tr} = \partial G \cdot \partial_{tr}\xi^{-1}$	$J \cdot x^{-1}$	2
Flux, isomorphic	J_{tr}	$J_{tr} = d_{tr}\xi \cdot dt^{-1} \cdot V^{-1}$	$x \cdot s^{-1} \cdot m^{-3}$	3
Advancement, n	$d_{tr}\xi_{H+/n}$	$d_{tr}\xi_{H+/n} = d_{tr}n_{H+} \cdot \nu_{H+}^{-1}$	mol	$4n$
Advancement, e	$d_{tr}\xi_{H+/e}$	$d_{tr}\xi_{H+/e} = d_{tr}e_{H+} \cdot \nu_{H+}^{-1}$	C	$4e$
Electric partial force, e	$F_{el/e}$	$F_{el/e} \equiv \Delta\Psi$	$V = J \cdot C^{-1}$	$5e$
Electric partial force, n	$F_{el/n}$	$\Delta\Psi \cdot F = 96.5 \cdot \Delta pH$	$kJ \cdot mol^{-1}$	$5n$
Chemical partial force, e	$F_{H+,d/e}$	$\Delta\mu_{H+}/F =$ $-\ln(10) \cdot RT/F \cdot \Delta pH$ $= -0.06 \cdot \Delta pH$	$J \cdot C^{-1}$ $J \cdot C^{-1}$	$6e$
Chemical partial force, n	$F_{H+,d/n}$	$\Delta\mu_{H+} = -\ln(10) \cdot RT \cdot \Delta pH$ $= -5.9 \cdot \Delta pH$	$J \cdot mol^{-1}$ $kJ \cdot mol^{-1}$	$6n$

831

832 1 to 4: An isomorphic motive entity or transformant, expressed in units x , is defined for any
 833 transformation, tr. $x = \text{mol}$ or C in the chemical or electrical format of proton translocation.

834 2: $\partial_{tr}G$ [J] is the partial Gibbs energy change in the advancement of transformation tr.

835 3: For $x = \text{C}$, flow is electric current, I_{el} [$\text{A} = \text{C} \cdot \text{s}^{-1}$], vector flux is electric current density per area, J_{el} ,
 836 and compartmental flux is electric current density per volume, I_{el} [$\text{A} \cdot \text{m}^{-3}$], all expressed in electrical
 837 format.

838 $4n$: For a chemical reaction, the advancement of reaction r is $d_r\xi_B = d_r n_B \cdot \nu_B^{-1}$ [mol]. The stoichiometric
 839 number is $\nu_B = -1$ or $\nu_B = 1$, depending on B being a product or substrate, respectively, in reaction
 840 r involving one mole of B. The conjugated *intensive* molar quantity, $F_{B,r} = \partial G / \partial_r \xi_B$ [$\text{J} \cdot \text{mol}^{-1}$], is the
 841 chemical force of reaction or *reaction-motive* force per stoichiometric amount of B. In reaction

842 kinetics, $d_r n_B$ is expressed as a volume-specific quantity, which is the partial contribution to the
 843 total concentration change of B, $d_r c_B = d_r n_B / V$ and $d c_B = d n_B / V$, respectively. In open systems with
 844 constant volume V , $d c_B = d_r c_B + d_e c_B$, where r indicates the *internal* reaction and e indicates the
 845 *external* flux of B into the unit volume of the system. At steady state the concentration does not
 846 change, $d c_B = 0$, when $d_r c_B$ is compensated for by the external flux of B, $d_r c_B = -d_e c_B$ (Gnaiger
 847 1993b). Alternatively, $d c_B = 0$ when B is held constant by different coupled reactions in which B
 848 acts as a substrate or a product.

849 4e: Scalar potential difference across the mitochondrial membrane. In a scalar electric transformation
 850 (flux of charge, *i.e.* volume-specific current, from the matrix space to the intermembrane and
 851 extramitochondrial space) the motive force is the difference of charge (**Box 2**). The endergonic
 852 direction of translocation is defined in **Fig. 2** as $H^+ \downarrow \rightarrow H^+ \uparrow$.

853 5n: $F = 96.5 \text{ (kJ}\cdot\text{mol}^{-1})/V$.

854 6: The electric partial force is independent of temperature (Note 5), but the chemical partial force
 855 depends on absolute temperature, T [K].

856 6e: R is the gas constant, and T is the absolute temperature. $RT/F \Delta \ln c$ yields force in the electrical
 857 format [$\text{J}\cdot\text{C}^{-1} = \text{V}$]. $RT/F = 2.479$ and 2.579 mV; $\ln(10) \cdot RT/F = 59.16$ and 61.54 mV at 298.15 and
 858 310.15 K (25 and 37 °C), respectively.

859 6n: $RT \Delta \ln c$ yields force in the chemical format [$\text{J}\cdot\text{mol}^{-1}$]. $RT = 2.479$ and 2.579 $\text{kJ}\cdot\text{mol}^{-1}$; $\ln(10) \cdot RT =$
 860 5.708 and 5.938 $\text{kJ}\cdot\text{mol}^{-1}$ at 298.15 and 310.15 K, respectively.

861

862 **Vectorial and scalar forces, and fluxes:** In chemical reactions and osmotic or diffusion
 863 processes occurring in a closed heterogeneous system, such as a chamber containing isolated
 864 mitochondria, scalar transformations occur without measured spatial direction but between
 865 separate compartments (translocation between the matrix and intermembrane space) or between
 866 energetically-separated chemical substances (reactions from substrates to products). Hence, the
 867 corresponding fluxes are not vectorial but scalar, and are expressed per volume and not per
 868 membrane area (**Box 2**). The corresponding motive forces are also scalar potential *differences*
 869 across the membrane (**Table 5**), without taking into account the *gradients* across the 6 nm thick
 870 mtIM (Rich 2003).

897 $F_{O_2,k}$ is the exergonic input force with a negative sign, and, $F_{H^+\uparrow}$, is the endergonic output force
 898 with a positive sign (**Box 3**). Ergodynamic efficiency is the ratio of output/input power, or the
 899 flux ratio times force ratio (Gnaiger 1993a,b),

$$900 \quad \varepsilon = \frac{P_{H^+\uparrow}}{-P_k} = \frac{J_{H^+\uparrow}}{J_{O_2,k}} \cdot \frac{F_{H^+\uparrow}}{-F_{O_2,k}}$$

901 The concept of incomplete coupling relates exclusively to the first term, *i.e.* the flux ratio, or
 902 $H^+\uparrow/O_2$ ratio (**Fig. 1**). Likewise, respirometric definitions of the $P\gg/O_2$ ratio and biochemical
 903 coupling efficiency (Section 3.2) consider flux ratios. In a completely coupled process, the
 904 power efficiency, ε , depends entirely on the force ratio, ranging from zero efficiency at an
 905 output force of zero, to the limiting output force and maximum efficiency of 1.0, when the total
 906 power of the coupled process, $P_t = P_k + P_{H^+\uparrow}$, equals zero, and any net flows are zero at
 907 ergodynamic equilibrium of a coupled process. Thermodynamic equilibrium is defined as the
 908 state when all potentials (all forces) are dissipated and equilibrate towards their minima of zero.
 909 In a fully or completely coupled process, output and input fluxes are directly proportional in a
 910 fixed ratio technically defined as a stoichiometric relationship (a gear ratio in a mechanical
 911 system). Such maximal stoichiometric output/input flux ratios are considered in OXPHOS
 912 analysis as the upper limits or mechanistic $H^+\uparrow/O_2$ and $P\gg/O_2$ ratios (**Fig. 1**).

913

914 **Coupled versus bound processes:** Since the chemiosmotic theory describes the
 915 mechanisms of coupling in OXPHOS, it may be interesting to ask if the electrical and chemical
 916 parts of proton translocation are coupled processes. This is not the case according to the
 917 definition of coupling. If the coupling mechanism is disengaged, the output process becomes
 918 independent of the input process, and both proceed in their downhill (exergonic) direction (**Fig.**
 919 **2**). It is not possible to physically uncouple the electrical and chemical processes, which are
 920 only *theoretically* partitioned as electrical and chemical components. The electrical and
 921 chemical partial protonmotive forces, $F_{el\uparrow}$ and $F_{H^+\uparrow,d}$, can be measured separately. In contrast,

922 the corresponding proton *flux*, J_{H^+} , is non-separable, *i.e.*, cannot be uncoupled. Then these are
 923 not *coupled* processes, but are defined as *bound* processes. The electrical and chemical parts
 924 are tightly bound partial forces, since the flux cannot be partitioned but expressed only in either
 925 an electrical or chemical isomorphic format, $J_{H^+/e}$ or $J_{H^+/n}$ (**Table 4**).

926

927 **4. Normalization: fluxes and flows**

928 The challenges of measuring mitochondrial respiratory flux are matched by those of
 929 normalization, whereby O_2 consumption may be considered as the numerator and normalization
 930 as the complementary denominator, which are tightly linked in reporting the measurements in
 931 a format commensurate with the requirements of a database.

932

933 *4.1. Flux per chamber volume*

934 When the reactor volume does not change during the reaction, which is typical for liquid
 935 phase reactions, the volume-specific *flux of a chemical reaction* r is the time derivative of the
 936 advancement of the reaction per unit volume, $J_{V,B} = d_r \zeta_B / dt \cdot V^{-1}$ [$(\text{mol} \cdot \text{s}^{-1}) \cdot \text{L}^{-1}$]. The *rate of*
 937 *concentration change* is dc_B / dt [$(\text{mol} \cdot \text{L}^{-1}) \cdot \text{s}^{-1}$], where concentration is $c_B = n_B / V$. It is helpful to
 938 make the subtle distinction between [$\text{mol} \cdot \text{s}^{-1} \cdot \text{L}^{-1}$] and [$\text{mol} \cdot \text{L}^{-1} \cdot \text{s}^{-1}$] for the fundamentally
 939 different quantities of volume-specific flux and rate of concentration change, which merge to a
 940 single expression only in closed systems. In open systems, external fluxes (such as O_2 supply)
 941 are distinguished from internal transformations (metabolic flux, O_2 consumption). In a closed
 942 system, external flows of all substances are zero and O_2 consumption (internal flow), I_{O_2}
 943 [$\text{pmol} \cdot \text{s}^{-1}$], causes a decline of the amount of O_2 in the system, n_{O_2} [nmol]. Normalization of
 944 these quantities for the volume of the system, V [$\text{L} = \text{dm}^3$], yields volume-specific O_2 flux, J_{V,O_2}
 945 $= I_{O_2} / V$ [$\text{nmol} \cdot \text{s}^{-1} \cdot \text{L}^{-1}$], and O_2 concentration, $[O_2]$ or $c_{O_2} = n_{O_2} / V$ [$\text{nmol} \cdot \text{mL}^{-1} = \mu\text{mol} \cdot \text{L}^{-1} = \mu\text{M}$].
 946 Instrumental background O_2 flux is due to external flux into a non-ideal closed respirometer,
 947 such that total volume-specific flux has to be corrected for instrumental background O_2 flux,

948 *i.e.* O₂ diffusion into or out of the instrumental chamber. J_{V,O_2} is relevant mainly for
949 methodological reasons and should be compared with the accuracy of instrumental resolution
950 of background-corrected flux, *e.g.* $\pm 1 \text{ nmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}$ (Gnaiger 2001). ‘Metabolic’ or catabolic
951 indicates O₂ flux, $J_{O_2,k}$, corrected for instrumental background O₂ flux and chemical background
952 O₂ flux due to autoxidation of chemical components added to the incubation medium.

953

954 4.2. System-specific and sample-specific normalization

955 Application of common and generally defined units is required for direct transfer of
956 reported results into a database. The second [s] is the *SI* unit for the base quantity *time*. It is also
957 the standard time-unit used in solution chemical kinetics. **Table 6** lists some conversion factors
958 to obtain *SI* units. The term *rate* is not sufficiently defined to be useful for a database (**Fig. 7**).
959 The inconsistency of the meanings of rate becomes fully apparent when considering Galileo
960 Galilei’s famous principle, that ‘bodies of different weight all fall at the same rate (have a
961 constant acceleration)’ (Coopersmith 2010).

962 **Extensive quantities:** An extensive quantity increases proportionally with system size.
963 The magnitude of an extensive quantity is completely additive for non-interacting subsystems,
964 such as mass or flow expressed per defined system. The magnitude of these quantities depends
965 on the extent or size of the system (Cohen *et al.* 2008).

966 **Size-specific quantities:** ‘The adjective *specific* before the name of an extensive quantity
967 is often used to mean *divided by mass*’ (Cohen *et al.* 2008). Mass-specific flux is flow divided
968 by mass of the system. A mass-specific quantity is independent of the extent of non-interacting
969 homogenous subsystems. Tissue-specific quantities are of fundamental interest in comparative
970 mitochondrial physiology, where *specific* refers to the *type* rather than *mass* of the tissue. The
971 term *specific*, therefore, must be further clarified, such that tissue mass-specific, *e.g.*, muscle
972 mass-specific quantities are defined.

973

974

975 **Fig. 7. Different meanings of rate**976 **may lead to confusion, if the**977 **normalization is not sufficiently**978 **specified.** Results are frequently979 expressed as mass-specific *flux*, J_m ,

980 per mg protein, dry or wet weight

981 (mass). Cell volume, V_{cell} , or982 mitochondrial volume, V_{mt} , may be


983 used for normalization (volume-

984 specific flux, $J_{V_{\text{cell}}}$ or $J_{V_{\text{mt}}}$), which then must be clearly distinguished from flux, J_V , expressed for985 methodological reasons per volume of the measurement system, or flow per cell, I_x .

986

987 **Molar quantities:** ‘The adjective *molar* before the name of an extensive quantity988 generally means *divided by amount of substance*’ (Cohen *et al.* 2008). The notion that all molar989 quantities then become *intensive* causes ambiguity in the meaning of *molar Gibbs energy*. It is

990 important to emphasize the fundamental difference between normalization for amount of

991 substance *in a system* or for amount of motive substance *in a transformation*. When the Gibbs992 energy of a system, G [J], is divided by the amount of substance B in the system, n_B [mol], a993 *size-specific* molar quantity is obtained, $G_B = G/n_B$ [J·mol⁻¹], which is not any force at all. In994 contrast, when the partial Gibbs energy change, ∂G [J], is divided by the motive amount of995 substance B in reaction r (advancement of reaction), $\partial_r \zeta_B$ [mol], the resulting intensive molar996 quantity, $F_{B,r} = \partial G / \partial_r \zeta_B$ [J·mol⁻¹], is the chemical motive force of reaction r involving 1 mol B997 (**Table 5**, Note 4).998 **Flow per system, I :** In analogy to electrical terms, flow as an extensive quantity (I ; per999 system) is distinguished from flux as a size-specific quantity (J ; per system size) (**Fig. 7**).1000 Electric current is flow, I_{el} [A = C·s⁻¹] per system (extensive quantity). When dividing this

1001 extensive quantity by system size (membrane area), a size-specific quantity is obtained, which
1002 is electric flux (electric current density), J_{el} [$A \cdot m^{-2} = C \cdot s^{-1} \cdot m^{-2}$].

1003 **Size-specific flux, J :** Metabolic O_2 flow per tissue increases as tissue mass is increased.
1004 Tissue mass-specific O_2 flux should be independent of the size of the tissue sample studied in
1005 the instrument chamber, but volume-specific O_2 flux (per volume of the instrument chamber,
1006 V) should increase in direct proportion to the amount of sample in the chamber. Accurate
1007 definition of the experimental system is decisive: whether the experimental chamber is the
1008 closed, open, isothermal or non-isothermal *system* with defined volume as part of the
1009 measurement apparatus, in contrast to the experimental *sample* in the chamber (**Table 6**).
1010 Volume-specific O_2 flux depends on mass-concentration of the sample in the chamber, but
1011 should be independent of the chamber volume. There are practical limitations to increasing the
1012 mass-concentration of the sample in the chamber, when one is concerned about crowding
1013 effects and instrumental time resolution.

1014 **Sample concentration C_{mX} :** Normalization for sample concentration is required for
1015 reporting respiratory data. Consider a tissue or cells as the sample, X , and the sample mass, m_X
1016 [mg] from which a mitochondrial preparation is obtained. The sample mass, m_X , is frequently
1017 measured as wet or dry weight, W_w or W_d [mg], or as amount of tissue or cell protein, $m_{Protein}$.
1018 In the case of permeabilized tissues, cells, and homogenates, the sample concentration, $C_{mX} =$
1019 m_X/V [$mg \cdot mL^{-1} = g \cdot L^{-1}$], is simply the mass of the subsample of tissue that is transferred into
1020 the instrument chamber. Part of the mitochondria from the tissue is lost during preparation of
1021 isolated mitochondria, and only a fraction of mitochondria is obtained, expressed as the
1022 mitochondrial yield (**Fig. 8**). At a high mitochondrial yield the sample of isolated mitochondria
1023 is more representative of the total mitochondrial population than in preparations characterized
1024 by low mitochondrial yield. Determination of the mitochondrial yield is based on measurement
1025 of the concentration of a mitochondrial marker in the tissue homogenate, $C_{mte,thom}$, which

1026 simultaneously provides information on the specific mitochondrial density in the sample (Fig.
1027 8).

1028

1029 **Table 6. Sample concentrations and normalization of flux with SI base units.**

Expression	Symbol	Definition	SI Unit	Notes
Sample				
Identity of sample	X	Cells, animals, patients		
Number of sample entities X	N_X	Number of cells, <i>etc.</i>	x	
Mass of sample X	m_X		kg	1
Mass of entity X	M_X	$M_X = m_X \cdot N_X^{-1}$	$\text{kg} \cdot \text{x}^{-1}$	1
Mitochondria				
Mitochondria	mt	$X = \text{mt}$		
Amount of mt-elements	mte	Quantity of mt-marker	x_{mte}	
Concentrations				
Sample number concentration	C_{NX}	$C_{NX} = N_X \cdot V^{-1}$	$\text{x} \cdot \text{m}^{-3}$	2
Sample mass concentration	C_{mX}	$C_{mX} = m_X \cdot V^{-1}$	$\text{kg} \cdot \text{m}^{-3}$	
Mitochondrial concentration	C_{mte}	$C_{\text{mte}} = \text{mte} \cdot V^{-1}$	$x_{\text{mte}} \cdot \text{m}^{-3}$	3
Specific mitochondrial density	D_{mte}	$D_{\text{mte}} = \text{mte} \cdot m_X^{-1}$	$x_{\text{mte}} \cdot \text{kg}^{-1}$	4
Mitochondrial content, mte per entity X	mte_X	$\text{mte}_X = \text{mte} \cdot N_X^{-1}$	$x_{\text{mte}} \cdot \text{x}^{-1}$	5
O₂ flow and flux				
Flow	I_{O_2}	Internal flow	$\text{mol} \cdot \text{s}^{-1}$	6
Volume-specific flux	J_{V,O_2}	$J_{V,\text{O}_2} = I_{\text{O}_2} \cdot V^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{m}^{-3}$	7
Flow per sample entity X	I_{X,O_2}	$I_{X,\text{O}_2} = J_{V,\text{O}_2} \cdot C_{NX}^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{x}^{-1}$	8
Mass-specific flux	J_{mX,O_2}	$J_{mX,\text{O}_2} = J_{V,\text{O}_2} \cdot C_{mX}^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{kg}^{-1}$	9
Mitochondria-specific flux	$J_{\text{mte},\text{O}_2}$	$J_{\text{mte},\text{O}_2} = J_{V,\text{O}_2} \cdot C_{\text{mte}}^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot x_{\text{mte}}^{-1}$	10

1031

1032 1 The SI prefix k is used for the SI base unit of mass (kg = 1,000 g). In praxis, various SI prefixes are
1033 used for convenience, to make numbers easily readable, e.g. 1 mg tissue, cell or mitochondrial mass
1034 instead of 0.000001 kg.

1035 2 In case $X = \text{cells}$, the sample number concentration is $C_{N_{\text{cell}}} = N_{\text{cell}} \cdot V^{-1}$, and volume may be expressed
1036 in [$\text{dm}^3 = \text{L}$] or [$\text{cm}^3 = \text{mL}$]. See **Table 7** for different sample types.

1037 3 mt-concentration is an experimental variable, dependent on sample concentration: (1) $C_{\text{mte}} = \text{mte} \cdot V^{-1}$;
1038 (2) $C_{\text{mte}} = \text{mte}_X \cdot C_{NX}$; (3) $C_{\text{mte}} = C_{mX} \cdot D_{\text{mte}}$.

1039 4 If the amount of mitochondria, mte, is expressed as mitochondrial mass, then D_{mte} is the mass
1040 fraction of mitochondria in the sample. If mte is expressed as mitochondrial volume, V_{mt} , and the

1041 mass of sample, m_X , is replaced by volume of sample, V_X , then D_{mte} is the volume fraction of
 1042 mitochondria in the sample.

1043 5 $mte_X = mte \cdot N_X^{-1} = C_{mte} \cdot C_{NX}^{-1}$.

1044 6 Entity O_2 can be replaced by other chemical entities B to study different reactions.

1045 7 l_{O_2} and V are defined per instrument chamber as a system of constant volume (and constant
 1046 temperature), which may be closed or open. l_{O_2} is abbreviated for $l_{O_2,r}$, *i.e.* the metabolic or internal
 1047 O_2 flow of the chemical reaction r in which O_2 is consumed, hence the negative stoichiometric
 1048 number, $v_{O_2} = -1$. $l_{O_2,r} = d_r n_{O_2} / dt \cdot v_{O_2}^{-1}$. If r includes all chemical reactions in which O_2 participates,
 1049 then $d_r n_{O_2} = dn_{O_2} - d_e n_{O_2}$, where dn_{O_2} is the change in the amount of O_2 in the instrument chamber
 1050 and $d_e n_{O_2}$ is the amount of O_2 added externally to the system. At steady state, by definition $dn_{O_2} = 0$,
 1051 hence $d_r n_{O_2} = -d_e n_{O_2}$.

1052 8 J_{V,O_2} is an experimental variable, expressed per volume of the instrument chamber.


1053 9 I_{X,O_2} is a physiological variable, depending on the size of entity X .

1054 10 There are many ways to normalize for a mitochondrial marker, that are used in different experimental
 1055 approaches: (1) $J_{mte,O_2} = J_{V,O_2} \cdot C_{mte}^{-1}$; (2) $J_{mte,O_2} = J_{V,O_2} \cdot C_{mX}^{-1} \cdot D_{mte}^{-1} = J_{mX,O_2} \cdot D_{mte}^{-1}$; (3) $J_{mte,O_2} =$
 1056 $J_{V,O_2} \cdot C_{mX}^{-1} \cdot mte_X^{-1} = I_{X,O_2} \cdot mte_X^{-1}$; (4) $J_{mte,O_2} = l_{O_2} \cdot mte^{-1}$.

1057

1058 Tissues can contain multiple cell populations which may have distinct mitochondrial
 1059 subtypes. Mitochondria are also in a constant state of flux due to highly dynamic fission and
 1060 fusion cycles, and can exist in multiple stages and sizes which may be altered by a range of
 1061 factors. The isolation of mitochondria (often achieved through differential centrifugation) can
 1062 therefore yield a subsample of the mitochondrial types present in a tissue, dependent on
 1063 isolation protocols utilized (*e.g.* centrifugation speed). This possible artefact should be taken
 1064 into account when planning experiments using isolated mitochondria. The tendency for
 1065 mitochondria of specific sizes to be enriched at different centrifugation speeds also has the
 1066 potential to allow the isolation of specific mitochondrial subpopulations and therefore the
 1067 analysis of mitochondria from multiple cell lineages within a single tissue.

1068



1069

Symbol	Definition [Units]
C_{mte}	Mitochondrial concentration in chamber [$x_{mte} \cdot L^{-1}$]
C_m	Sample mass concentration in chamber [$g \cdot L^{-1}$]
D_{mte}	Specific mte-density per tissue mass [$x_{mte} \cdot g^{-1}$]
J_{m,O_2}	Mass-specific O_2 flux [$nmol \cdot s^{-1} \cdot g^{-1}$]
J_{mte,O_2}	Mitochondria-specific O_2 flux [$nmol \cdot s^{-1} \cdot x_{mte}^{-1}$]
mte	Amount of mitochondrial elements [x_{mte}]
m_{thom}	Mass of tissue in the homogenate [g]
Y_{mt}	Yield of isolated mitochondria

Respirometer chamber

Homogenate

$v_{thom,1}$

V

$$C_m = C_{m,thom} \frac{v_{thom,1}}{V}$$

$$C_{mte} = C_m \cdot D_{mte}$$

$$J_{m,O_2} = \frac{J_{V,O_2}}{C_m}$$

$$J_{mte,O_2} = \frac{J_{m,O_2}}{D_{mte}}$$

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

Fig. 8. Normalization of volume-specific flux of isolated mitochondria and tissue

homogenate. A: Mitochondrial yield, Y_{mt} , in preparation of isolated mitochondria. $v_{thom,1}$

and $v_{stock,1}$ are the volumes transferred from the total volume, V_{thom} and V_{stock} , respectively.

$mte_{thom,1}$ is the amount of mitochondrial elements in volume $v_{thom,1}$ used for isolation. **B:**

In respirometry with homogenate, $v_{thom,1}$ is transferred directly into the respirometer

chamber. See **Table 6** for further explanation of symbols.

1080
1081**Table 7. Some useful abbreviations of various sample types, X.**

Identity of sample	X
Mitochondrial preparation	mtprep
Isolated mitochondria	imt
Tissue homogenate	thom
Permeabilized tissue	pti
Permeabilized fibre	pfi
Permeabilized cell	pce
Cell	ce
Organism	org

1082

1083 **Mass-specific flux, J_{mX,O_2} :** Mass-specific flux is obtained by expressing respiration per
1084 mass of sample, m_X [mg]. X is the type of sample, *e.g.*, tissue homogenate, permeabilized fibres
1085 or cells. Volume-specific flux is divided by mass concentration of X , $J_{mX,O_2} = J_{V,O_2}/C_{mX}$; or flow
1086 per cell is divided by mass per cell, $J_{mcell,O_2} = I_{cell,O_2}/M_{cell}$. If mass-specific O_2 flux is constant
1087 and independent of sample size (expressed as mass), then there is no interaction between the
1088 subsystems. A 1.5 mg and a 3.0 mg muscle sample respire at identical mass-specific flux.
1089 Mass-specific O_2 flux, however, may change with the mass of a tissue sample, cells or isolated
1090 mitochondria in the measuring chamber, in which case the nature of the interaction becomes an
1091 issue. Optimization of cell density and arrangement is generally important and particularly in
1092 experiments carried out in wells, considering the confluency of the cell monolayer or clumps
1093 of cells (Salabei *et al.* 2014).

1094 **Number concentration, C_{NX} :** The experimental *number concentration* of sample in the
1095 case of cells or animals, *e.g.*, nematodes is $C_{NX} = N_X/V$ [$x \cdot mL^{-1}$], where N_X is the number of
1096 cells or organisms in the chamber (**Table 6**).

1097 **Flow per sample entity, I_{X,O_2} :** A special case of normalization is encountered in
1098 respiratory studies with permeabilized (or intact) cells. If respiration is expressed per cell, the

1099 O₂ flow per measurement system is replaced by the O₂ flow per cell, $I_{\text{cell},\text{O}_2}$ (**Table 6**). O₂ flow
1100 can be calculated from volume-specific O₂ flux, J_{V,O_2} [nmol·s⁻¹·L⁻¹] (per V of the measurement
1101 chamber [L]), divided by the number concentration of cells, $C_{N_{\text{ce}}} = N_{\text{ce}}/V$ [cell·L⁻¹], where N_{ce}
1102 is the number of cells in the chamber. Cellular O₂ flow can be compared between cells of
1103 identical size. To take into account changes and differences in cell size, further normalization
1104 is required to obtain cell size-specific or mitochondrial marker-specific O₂ flux (Renner *et al.*
1105 2003).

1106 The complexity changes when the sample is a whole organism studied as an experimental
1107 model. The well-established scaling law in respiratory physiology reveals a strong interaction
1108 of O₂ consumption and individual body mass of an organism, since *basal* metabolic rate (flow)
1109 does not increase linearly with body mass, whereas *maximum* mass-specific O₂ flux, $\dot{V}_{\text{O}_2\text{max}}$ or
1110 $\dot{V}_{\text{O}_2\text{peak}}$, is approximately constant across a large range of individual body mass (Weibel and
1111 Hoppeler 2005), with individuals, breeds, and certain species deviating substantially from this
1112 general relationship. $\dot{V}_{\text{O}_2\text{peak}}$ of human endurance athletes is 60 to 80 mL O₂·min⁻¹·kg⁻¹ body
1113 mass, converted to $J_{m,\text{O}_2\text{peak}}$ of 45 to 60 nmol·s⁻¹·g⁻¹ (Gnaiger 2014; **Table 8**).

1114

1115 4.3. Normalization for mitochondrial content


1116 Normalization is a problematic subject and it is essential to consider the question of the
1117 study. If the study aims to compare tissue performance, such as the effects of a certain treatment
1118 on a specific tissue, then normalization can be successful, using tissue mass or protein content,
1119 for example. If the aim, however, is to find differences of mitochondrial function independent
1120 of mitochondrial density (**Table 6**), then normalization to a mitochondrial marker is imperative
1121 (**Fig. 9**). However, one cannot assume that quantitative changes in various markers such as
1122 mitochondrial proteins necessarily occur in parallel with one another. It is important to first
1123 establish that the marker chosen is not selectively altered by the performed treatment. In
1124 conclusion, the normalization must reflect the question under investigation to reach a satisfying

1125 answer. On the other hand, the goal of comparing results across projects and institutions
1126 requires some standardization on normalization for entry into a databank.

1127 **Mitochondrial concentration, C_{mte} , and mitochondrial markers:** It is important that
1128 mitochondrial concentration in the tissue and the measurement chamber be quantified, as a
1129 physiological output and result of mitochondrial biogenesis and degradation, and as a quantity
1130 for normalization in functional analyses. Mitochondrial organelles comprise a cellular
1131 reticulum that is in a continual flux of fusion and fission. Hence the definition of an "amount"
1132 of mitochondria is often misconceived: mitochondria cannot be counted as a number of
1133 occurring elements. Therefore, quantification of the "amount" of mitochondria depends on
1134 measurement of chosen mitochondrial markers. 'Mitochondria are the structural and functional
1135 elemental units of cell respiration' (Gnaiger 2014). The quantity of a mitochondrial marker can
1136 be considered as the measurement of the amount of *elemental mitochondrial units* or
1137 *mitochondrial elements*, mte. However, since mitochondrial quality changes under certain
1138 stimuli, particularly in mitochondrial dysfunction and after exercise training (Pesta *et al.* 2011;
1139 Campos *et al.* 2017), some markers can vary while other markers are unchanged. (1)
1140 Mitochondrial volume and membrane area are structural markers, whereas mitochondrial
1141 protein mass is frequently used as a marker for isolated mitochondria. (2) Molecular and
1142 enzymatic mitochondrial markers (amounts or activities) can be selected as matrix markers,
1143 *e.g.*, citrate synthase activity, mtDNA; mtIM-markers, *e.g.*, cytochrome *c* oxidase activity, *aa₃*
1144 content, cardiolipin, or mtOM-markers, *e.g.*, TOM20. (3) Extending the measurement of
1145 mitochondrial marker enzyme activity to mitochondrial pathway capacity, measured as ET- or
1146 OXPHOS-capacity, can be considered as an integrative functional mitochondrial marker.

1147 Depending on the type of mitochondrial marker, the mitochondrial elements, mte, are
1148 expressed in marker-specific units. Although concentration and density are used synonymously
1149 in physical chemistry, it is recommended to distinguish *experimental mitochondrial*
1150 *concentration*, $C_{mte} = mte/V$ and *physiological mitochondrial density*, $D_{mte} = mte/m_X$. Then

1151 mitochondrial density is the amount of mitochondrial elements per mass of tissue (**Fig. 9**). The
 1152 former is mitochondrial density multiplied by sample mass concentration, $C_{mte} = D_{mte} \cdot C_{mX}$, or
 1153 mitochondrial content multiplied by sample number concentration, $C_{mte} = mte_X \cdot C_{NX}$ (**Table 6**).
 1154



1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

Fig. 9. Structure-function analysis of performance of an organism, organ or tissue, or a cell (sample entity X). O₂ flow, I_{X,O_2} , is the product of performance per functional element (element function, mitochondria-specific flux), element density (mitochondrial density, D_{mte}), and size of entity X (mass M_X). (A) Structured analysis: performance is the product of mitochondrial *function* (mt-specific flux) and *structure* (functional elements; D_{mte} times mass of X). (B) Unstructured analysis: performance is the product of *entity mass-specific flux*, $J_{mX,O_2} = I_{X,O_2}/M_X = I_{O_2}/m_X$ [$\text{mol} \cdot \text{s}^{-1} \cdot \text{kg}^{-1}$] and *size of entity*, expressed as mass of X; $M_X = m_X \cdot N_X^{-1}$ [$\text{kg} \cdot \text{x}^{-1}$]. See **Table 6 for further explanation of quantities and units. Modified from Gnaiger (2014).**

1170 **Mitochondria-specific flux, $J_{\text{mte},\text{O}_2}$:** Volume-specific metabolic O_2 flux depends on: (1)
 1171 the sample concentration in the volume of the instrument chamber, C_{mX} , or C_{NX} ; (2) the
 1172 mitochondrial density in the sample, $D_{\text{mte}} = \text{mte}/m_X$ or $\text{mte}_X = \text{mte}/N_X$; and (3) the specific
 1173 mitochondrial activity or performance per elemental mitochondrial unit, $J_{\text{mte},\text{O}_2} = J_{V,\text{O}_2}/C_{\text{mte}}$
 1174 (**Table 6**). Obviously, the numerical results for $J_{\text{mte},\text{O}_2}$ vary according to the type of
 1175 mitochondrial marker chosen for measurement of mte and $C_{\text{mte}} = \text{mte}/V$.

1176 4.4. Evaluation of mitochondrial markers

1177 Different methods are implicated in quantification of mitochondrial markers and have
 1178 different strengths. Some problems are common for all mitochondrial markers, mte: (1)
 1179 Accuracy of measurement is crucial, since even a highly accurate and reproducible
 1180 measurement of O_2 flux results in an inaccurate and noisy expression normalized for a biased
 1181 and noisy measurement of a mitochondrial marker. This problem is acute in mitochondrial
 1182 respiration because the denominators used (the mitochondrial markers) are often very small
 1183 moieties whose accurate and precise determination is difficult. This problem can be avoided
 1184 when O_2 fluxes measured in substrate-uncoupler-inhibitor titration protocols are normalized for
 1185 flux in a defined respiratory reference state, which is used as an *internal* marker and yields flux
 1186 control ratios, *FCRs* (**Fig. 7**). *FCRs* are independent of any *externally* measured markers and,
 1187 therefore, are statistically very robust, considering the limitations of ratios in general (Jasienski
 1188 and Bazzaz 1999). *FCRs* indicate qualitative changes of mitochondrial respiratory control, with
 1189 highest quantitative resolution, separating the effect of mitochondrial density or concentration
 1190 on J_{mX,O_2} and I_{X,O_2} from that of function per elemental mitochondrial marker, $J_{\text{mte},\text{O}_2}$ (Pesta *et*
 1191 *al.* 2011; Gnaiger 2014). (2) If mitochondrial quality does not change and only the amount of
 1192 mitochondria, defined by the chosen mitochondrial marker, varies as a determinant of mass-
 1193 specific flux, any marker is equally qualified in principle; then in practice selection of the
 1194 optimum marker depends only on the accuracy and precision of measurement of the
 1195 mitochondrial marker. (3) If mitochondrial flux control ratios change, then there may not be

1196 any best mitochondrial marker. In general, measurement of multiple mitochondrial markers
1197 enables a comparison and evaluation of normalization for a variety of mitochondrial markers.
1198 Particularly during postnatal development, the activity of marker enzymes, such as cytochrome
1199 *c* oxidase and citrate synthase, follows different time courses (Drahota et al. 2004). Evaluation
1200 of mitochondrial markers in healthy controls is insufficient for providing guidelines for
1201 application in the diagnosis of pathological states and specific treatments.

1202 In line with the concept of the respiratory control ratio (Chance and Williams 1955a), the
1203 most readily used normalization is that of flux control ratios and flux control factors (Gnaiger
1204 2014). Selection of the state of maximum flux in a protocol as the reference state has the
1205 advantages of (1) internal normalization, (2) statistical linearization of the response in the range
1206 of 0 to 1, and (3) consideration of maximum flux for integrating a very large number of
1207 elemental steps in the OXPHOS- or ET-pathways. This reduces the risk of selecting a functional
1208 marker that is specifically altered by the treatment or pathodology, yet increases the chance that
1209 the highly integrative pathway is disproportionately affected, *e.g.* the OXPHOS- rather than
1210 ET-pathway in case of an enzymatic defect in the phosphorylation-pathway. In this case,
1211 additional information can be obtained by reporting flux control ratios based on a reference
1212 state which indicates stable tissue-mass specific flux. Stereological determination of
1213 mitochondrial content via two-dimensional transmission electron microscopy can have
1214 limitations due to the dynamics of mitochondrial size (Meinild Lundby *et al.* 2017). Accurate
1215 determination of three-dimensional volume by two-dimensional microscopy can be both time
1216 consuming and statistically challenging (Larsen *et al.* 2012). Using mitochondrial marker
1217 enzymes (citrate synthase activity, Complex I–IV amount or activity) for normalization of flux
1218 is limited in part by the same factors that apply to the use of flux control ratios. Strong
1219 correlations between various mitochondrial markers and citrate synthase activity (Reichmann
1220 et al. 1985; Boushel *et al.* 2007; Mogensen *et al.* 2007) are expected in a specific tissue of
1221 healthy subjects and in disease states not specifically targeting citrate synthase. Citrate synthase

1222 activity is acutely modifiable by exercise (Tonkonogi *et al.* 1997; Leek *et al.* 2001). Evaluation
1223 of mitochondrial markers related to a selected age and sex cohort cannot be extrapolated to
1224 provide recommendations for normalization in respirometric diagnosis of disease, in different
1225 states of development and ageing, different cell types, tissues, and species. mtDNA normalised
1226 to nDNA via qPCR is correlated to functional mitochondrial markers including OXPHOS- and
1227 ET-capacity in some cases (Puntschart *et al.* 1995; Wang *et al.* 1999; Menshikova *et al.* 2006;
1228 Boushel *et al.* 2007), but lack of such correlations have been reported (Menshikova *et al.* 2005;
1229 Schultz and Wiesner 2000; Pesta *et al.* 2011). Several studies indicate a strong correlation
1230 between cardiolipin content and increase in mitochondrial functionality with exercise
1231 (Menshikova *et al.* 2005; Menshikova *et al.* 2007; Larsen *et al.* 2012; Faber *et al.* 2014), but its
1232 use as a general mitochondrial biomarker in disease remains questionable.

1233

1234 4.5. Conversion: units and normalization

1235 Many different units have been used to report the rate of oxygen consumption, OCR
1236 (**Table 8**). *SI* base units provide the common reference for introducing the theoretical principles
1237 (**Fig. 7**), and are used with appropriately chosen *SI* prefixes to express numerical data in the
1238 most practical format, with an effort towards unification within specific areas of application
1239 (**Table 9**). For studies of cells, we recommend that respiration be expressed, as far as possible,
1240 as (1) O₂ flux normalized for a mitochondrial marker, for separation of the effects of
1241 mitochondrial quality and content on cell respiration (this includes *FCRs* as a normalization for
1242 a functional mitochondrial marker); (2) O₂ flux in units of cell volume or mass, for comparison
1243 of respiration of cells with different cell size (Renner *et al.* 2003) and with studies on tissue
1244 preparations, and (3) O₂ flow in units of attomole (10⁻¹⁸ mol) of O₂ consumed by each cell in a
1245 second [amol·s⁻¹·cell⁻¹], numerically equivalent to [pmol·s⁻¹·10⁻⁶ cells]. This convention allows
1246 information to be easily used when designing experiments in which oxygen consumption must
1247 be considered. For example, to estimate the volume-specific O₂ flux in an instrument chamber

1248 that would be expected at a particular cell number concentration, one simply needs to multiply
 1249 the flow per cell by the number of cells per volume of interest. This provides the amount of O₂
 1250 [mol] consumed per time [s⁻¹] per unit volume [L⁻¹]. At an O₂ flow of 100 amol·s⁻¹·cell⁻¹ and a
 1251 cell density of 10⁹ cells·L⁻¹ (10⁶ cells·mL⁻¹), the volume-specific O₂ flux is 100 nmol·s⁻¹·L⁻¹ (100
 1252 pmol·s⁻¹·mL⁻¹).

1253 Although volume is expressed as m³ using the *SI* base unit, the litre [dm³] is the basic unit
 1254 of volume for concentration and is used for most solution chemical kinetics. If one multiplies
 1255 $I_{\text{cell},\text{O}_2}$ by C_{Ncell} , then the result will not only be the amount of O₂ [mol] consumed per time [s⁻¹]
 1256 in one litre [L⁻¹], but also the change in the concentration of oxygen per second (for any volume
 1257 of an ideally closed system). This is ideal for kinetic modeling as it blends with chemical rate
 1258 equations where concentrations are typically expressed in mol·L⁻¹ (Wagner *et al.* 2011). In
 1259 studies of multinuclear cells, such as differentiated skeletal muscle cells, it is easy to determine
 1260 the number of nuclei but not the total number of cells. A generalized concept, therefore, is
 1261 obtained by substituting cells by nuclei as the sample entity. This does not hold, however, for
 1262 enucleated platelets.

1263

1264 4.5. Conversion: oxygen, proton and ATP flux

1265 $J_{\text{O}_2,k}$ is coupled in mitochondrial steady states to proton cycling, $J_{\text{H}^+\infty} = J_{\text{H}^+\uparrow} = J_{\text{H}^+\downarrow}$ (**Fig.**
 1266 **2**). $J_{\text{H}^+\uparrow/n}$ and $J_{\text{H}^+\downarrow/n}$ [nmol·s⁻¹·L⁻¹] are converted into electrical units, $J_{\text{H}^+\uparrow/e}$ [mC·s⁻¹·L⁻¹ = mA·L⁻¹]
 1267 = $J_{\text{H}^+\uparrow/n}$ [nmol·s⁻¹·L⁻¹]· F [C·mol⁻¹]·10⁻⁶ (**Table 4**). At a $J_{\text{H}^+\uparrow}/J_{\text{O}_2,k}$ ratio or H⁺↑/O₂ of 20 (H⁺↑/O =
 1268 10), a volume-specific O₂ flux of 100 nmol·s⁻¹·L⁻¹ would correspond to a proton flux of 2,000
 1269 nmol H⁺↑·s⁻¹·L⁻¹ or volume-specific current of 193 mA·L⁻¹.

$$1270 \quad J_{\text{V,H}^+\uparrow/e} [\text{mA}\cdot\text{L}^{-1}] = J_{\text{V,H}^+\uparrow/n} \cdot F \cdot 10^{-6} [\text{nmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}\cdot\text{mC}\cdot\text{nmol}^{-1}] \quad (\text{Eq. 3.1})$$

$$1271 \quad J_{\text{V,H}^+\uparrow/e} [\text{mA}\cdot\text{L}^{-1}] = J_{\text{V,O}_2} \cdot (\text{H}^+\uparrow/\text{O}_2) \cdot F \cdot 10^{-6} [\text{mC}\cdot\text{s}^{-1}\cdot\text{L}^{-1} = \text{mA}\cdot\text{L}^{-1}] \quad (\text{Eq. 3.2})$$

1272

1273 **Table 8. Conversion of various units used in respirometry and**
 1274 **ergometry.** e is the number of electrons or reducing equivalents. z_B is the
 1275 charge number of entity B.
 1276

1 Unit	x	Multiplication factor	SI-Unit	Note
ng.atom O·s ⁻¹	(2 e)	0.5	nmol O ₂ ·s ⁻¹	
ng.atom O·min ⁻¹	(2 e)	8.33	pmol O ₂ ·s ⁻¹	
natom O·min ⁻¹	(2 e)	8.33	pmol O ₂ ·s ⁻¹	
nmol O ₂ ·min ⁻¹	(4 e)	16.67	pmol O ₂ ·s ⁻¹	
nmol O ₂ ·h ⁻¹	(4 e)	0.2778	pmol O ₂ ·s ⁻¹	
mL O ₂ ·min ⁻¹ at STPD ^a		0.744	μmol O ₂ ·s ⁻¹	1
W = J/s at -470 kJ/mol O ₂		-2.128	μmol O ₂ ·s ⁻¹	
mA = mC·s ⁻¹	(z _{H+} = 1)	10.36	nmol H ⁺ ·s ⁻¹	2
mA = mC·s ⁻¹	(z _{O2} = 4)	2.59	nmol O ₂ ·s ⁻¹	2
nmol H ⁺ ·s ⁻¹	(z _{H+} = 1)	0.09649	mA	3
nmol O ₂ ·s ⁻¹	(z _{O2} = 4)	0.38594	mA	3

1277

1278 1 At standard temperature and pressure dry (STPD: 0 °C = 273.15 K and 1 atm =
 1279 101.325 kPa = 760 mmHg), the molar volume of an ideal gas, V_m , and V_{m,O_2} is
 1280 22.414 and 22.392 L·mol⁻¹ respectively. Rounded to three decimal places, both
 1281 values yield the conversion factor of 0.744. For comparison at NTPD (20 °C),
 1282 V_{m,O_2} is 24.038 L·mol⁻¹. Note that the *SI* standard pressure is 100 kPa.

1283 2 The multiplication factor is $10^6/(z_B \cdot F)$.

1284 3 The multiplication factor is $z_B \cdot F/10^6$.

1285

1286

1287

1288

1289

1290 **Table 9. Conversion of units with preservation of numerical values.**

Name	Frequently used unit	Equivalent unit	Note
Volume-specific flux, J_{V,O_2}	$\text{pmol}\cdot\text{s}^{-1}\cdot\text{mL}^{-1}$ $\text{mmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}$	$\text{nmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}$ $\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}$	1
Cell-specific flow, I_{O_2}	$\text{pmol}\cdot\text{s}^{-1}\cdot 10^{-6}$ cells	$\text{amol}\cdot\text{s}^{-1}\cdot\text{cell}^{-1}$	2
	$\text{pmol}\cdot\text{s}^{-1}\cdot 10^{-9}$ cells	$\text{zmol}\cdot\text{s}^{-1}\cdot\text{cell}^{-1}$	3
Cell number concentration, C_{Nce}	10^6 cells $\cdot\text{mL}^{-1}$	10^9 cells $\cdot\text{L}^{-1}$	
Mitochondrial protein concentration, C_{mte}	0.1 mg $\cdot\text{mL}^{-1}$	0.1 g $\cdot\text{L}^{-1}$	
Mass-specific flux, J_{m,O_2}	$\text{pmol}\cdot\text{s}^{-1}\cdot\text{mg}^{-1}$	$\text{nmol}\cdot\text{s}^{-1}\cdot\text{g}^{-1}$	4
Catabolic power, $P_{O_2,k}$	$\mu\text{W}\cdot 10^{-6}$ cells	$\text{pW}\cdot\text{cell}^{-1}$	1
Volume	1,000 L	m^3 (1,000 kg)	
	L	dm^3 (kg)	
	mL	cm^3 (g)	
	μL	mm^3 (mg)	
	fL	μm^3 (pg)	
Amount of substance concentration	$\text{M} = \text{mol}\cdot\text{L}^{-1}$	$\text{mol}\cdot\text{dm}^{-3}$	

1291
1292 1 pmol: picomole = 10^{-12} mol
1293 2 amol: attomole = 10^{-18} mol
1294 3 zmol: zeptomole = 10^{-21} mol
1295 4 nmol: nanomole = 10^{-9} mol
1296

1297 ET-capacity in various human cell types including HEK 293, primary HUVEC and fibroblasts
1298 ranges from 50 to 180 $\text{amol}\cdot\text{s}^{-1}\cdot\text{cell}^{-1}$, measured in intact cells in the noncoupled state (see
1299 Gnaiger 2014). At 100 $\text{amol}\cdot\text{s}^{-1}\cdot\text{cell}^{-1}$ corrected for ROX (corresponding to a catabolic power
1300 of -48 $\text{pW}\cdot\text{cell}^{-1}$), the current across the mt-membranes, I_e , approximates 193 $\text{pA}\cdot\text{cell}^{-1}$ or 0.2
1301 nA per cell. See Rich (2003) for an extension of quantitative bioenergetics from the molecular
1302 to the human scale, with a transmembrane proton flux equivalent to 520 A in an adult at a
1303 catabolic power of -110 W. Modelling approaches illustrate the link between proton motive
1304 force and currents (Willis *et al.* 2016).For NADH- and succinate-linked respiration, the
1305 mechanistic $\text{P}\gg/\text{O}_2$ ratio (referring to the full 4 electron reduction of O_2) is calculated at $20/3.7$
1306 and $12/3.7$, respectively (Eq. 4) equal to 5.4 and 3.3. The classical $\text{P}\gg/\text{O}$ ratios (referring to the
1307 2 electron reduction of 0.5 O_2) are 2.7 and 1.6 (Watt *et al.* 2010), in direct agreement with the
1308 measured $\text{P}\gg/\text{O}$ ratio for succinate of 1.58 ± 0.02 (Gnaiger *et al.* 2000; for detailed reviews see
1309 Wikström and Hummer 2012; Sazanov 2015),

1310
$$P_{\gg}/O_2 = (H^{\uparrow}/O_2)/(H^{\downarrow}/P_{\gg}) \quad (\text{Eq. 4})$$

1311 In summary (**Fig. 1**),

1312
$$J_{V,P_{\gg}} [\text{nmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}] = J_{V,O_2}\cdot(H^{\uparrow}/O_2)/(H^{\downarrow}/P_{\gg}) \quad (\text{Eq. 5.1})$$

1313
$$J_{V,P_{\gg}} [\text{nmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}] = J_{V,O_2}\cdot(P_{\gg}/O_2) \quad (\text{Eq. 5.2})$$

1314 We consider isolated mitochondria as powerhouses and proton pumps as molecular machines
 1315 to relate experimental results to energy metabolism of the intact cell. The cellular P_{\gg}/O_2 based
 1316 on oxidation of glycogen is increased by the glycolytic (fermentative) substrate-level
 1317 phosphorylation of 3 P_{\gg}/Glyc , *i.e.*, 0.5 mol P_{\gg} for each mol O_2 consumed in the complete
 1318 oxidation of a mol glycosyl unit (Glyc). Adding 0.5 to the mitochondrial P_{\gg}/O_2 ratio of 5.4
 1319 yields a bioenergetic cell physiological P_{\gg}/O_2 ratio close to 6. Two NADH equivalents are
 1320 formed during glycolysis and transported from the cytosol into the mitochondrial matrix, either
 1321 by the malate-aspartate shuttle or by the glycerophosphate shuttle resulting in different
 1322 theoretical yield of ATP generated by mitochondria, the energetic cost of which potentially
 1323 must be taken into account. Considering also substrate-level phosphorylation in the TCA cycle,
 1324 this high P_{\gg}/O_2 ratio not only reflects proton translocation and OXPHOS studied in isolation,
 1325 but integrates mitochondrial physiology with energy transformation in the living cell (Gnaiger
 1326 1993a).

1327

1328 **5. Conclusions**

1329 MitoEAGLE can serve as a gateway to better diagnose mitochondrial respiratory defects
 1330 linked to genetic variation, age-related health risks, sex-specific mitochondrial performance,
 1331 lifestyle with its effects on degenerative diseases, and thermal and chemical environment. The
 1332 present recommendations on coupling control states and rates, linked to the concept of the
 1333 protonmotive force (Part 1) will be extended in a series of reports on pathway control of
 1334 mitochondrial respiration, respiratory states in intact cells, and harmonization of experimental
 1335 procedures.

1336

1337 Box 5: Mitochondrial and cell respiration

1338 Mitochondrial and cell respiration is the process of highly exergonic and exothermic energy
1339 transformation in which scalar redox reactions are coupled to vectorial ion translocation across
1340 a semipermeable membrane, which separates the small volume of a bacterial cell or
1341 mitochondrion from the larger volume of its surroundings. The electrochemical exergy can be
1342 partially conserved in the phosphorylation of ADP to ATP or in ion pumping, or dissipated in
1343 an electrochemical short-circuit. Respiration is thus clearly distinguished from fermentation as
1344 the counterpart of cellular core energy metabolism. Respiration is separated in mitochondrial
1345 preparations from the partial contribution of fermentative pathways of the intact cell. According
1346 to this definition, residual oxygen consumption, as measured after inhibition of mitochondrial
1347 electron transfer, does not belong to the class of catabolic reactions and is, therefore, subtracted
1348 from total oxygen consumption to obtain baseline-corrected respiration.

1349

1350 The optimal choice for expressing mitochondrial and cell respiration (**Box 5**) as O₂ flow
1351 per biological system, and normalization for specific tissue-markers (volume, mass, protein)
1352 and mitochondrial markers (volume, protein, content, mtDNA, activity of marker enzymes,
1353 respiratory reference state) is guided by the scientific question under study. Interpretation of
1354 the obtained data depends critically on appropriate normalization, and therefore reporting rates
1355 merely as nmol·s⁻¹ is discouraged, since it restricts the analysis to intra-experimental
1356 comparison of relative (qualitative) differences. Expressing O₂ consumption per cell may not
1357 be possible when dealing with tissues. For studies with mitochondrial preparations, we
1358 recommend that normalizations be provided as far as possible: (1) on a per cell basis as O₂ flow
1359 (a biophysical normalization); (2) per g cell or tissue protein, or per cell or tissue mass as mass-
1360 specific O₂ flux (a cellular normalization); and (3) per mitochondrial marker as mt-specific flux
1361 (a mitochondrial normalization). With information on cell size and the use of multiple

1362 normalizations, maximum potential information is available (Renner *et al.* 2003; Wagner *et al.*
1363 2011; Gnaiger 2014). When using isolated mitochondria, mitochondrial protein is a frequently
1364 applied mitochondrial marker, the use of which is basically restricted to isolated mitochondria.
1365 Mitochondrial markers, such as citrate synthase activity as an enzymatic matrix marker, provide
1366 a link to the tissue of origin on the basis of calculating the mitochondrial yield, *i.e.*, the fraction
1367 of mitochondrial marker obtained from a unit mass of tissue.

1368

1369 **Acknowledgements**

1370 We thank M. Beno for management assistance. Supported by COST Action CA15203
1371 MitoEAGLE and K-Regio project MitoFit (EG).

1372 **Competing financial interests:** E.G. is founder and CEO of Oroboros Instruments, Innsbruck,
1373 Austria.

1374

1375 **6. References** (*incomplete; www links will be deleted in the final version*)

1376 Altmann R (1894) Die Elementarorganismen und ihre Beziehungen zu den Zellen. Zweite
1377 vermehrte Auflage. Verlag Von Veit & Comp, Leipzig:160 pp. -

1378 www.mitoeagle.org/index.php/Altmann_1894_Verlag_Von_Veit_%26_Comp

1379 Birkedal R, Laasmaa M, Vendelin M (2014) The location of energetic compartments affects
1380 energetic communication in cardiomyocytes. *Front Physiol* 5:376. doi:

1381 10.3389/fphys.2014.00376. eCollection 2014. PMID: 25324784

1382 Breton S, Beaupré HD, Stewart DT, Hoeh WR, Blier PU (2007) The unusual system of

1383 doubly uniparental inheritance of mtDNA: isn't one enough? *Trends Genet* 23:465-74.

1384 Brown GC (1992) Control of respiration and ATP synthesis in mammalian mitochondria and
1385 cells. *Biochem J* 284:1-13. - www.mitoeagle.org/index.php/Brown_1992_Biochem_J

1386 Campos JC, Queliconi BB, Bozi LHM, Bechara LRG, Dourado PMM, Andres AM, Jannig

1387 PR, Gomes KMS, Zambelli VO, Rocha-Resende C, Guatimosim S, Brum PC, Mochly-

- 1388 Rosen D, Gottlieb RA, Kowaltowski AJ, Ferreira JCB (2017) Exercise reestablishes
1389 autophagic flux and mitochondrial quality control in heart failure. *Autophagy* 13:1304-
1390 317.
- 1391 Chance B, Williams GR (1955a) Respiratory enzymes in oxidative phosphorylation. I.
1392 Kinetics of oxygen utilization. *J Biol Chem* 217:383-93. -
1393 http://www.mitoeagle.org/index.php/Chance_1955_J_Biol_Chem-I
- 1394 Chance B, Williams GR (1955b) Respiratory enzymes in oxidative phosphorylation: III. The
1395 steady state. *J Biol Chem* 217:409-27. -
1396 www.mitoeagle.org/index.php/Chance_1955_J_Biol_Chem-III
- 1397 Chance B, Williams GR (1955c) Respiratory enzymes in oxidative phosphorylation. IV. The
1398 respiratory chain. *J Biol Chem* 217:429-38. -
1399 www.mitoeagle.org/index.php/Chance_1955_J_Biol_Chem-IV
- 1400 Chance B, Williams GR (1956) The respiratory chain and oxidative phosphorylation. *Adv*
1401 *Enzymol Relat Subj Biochem* 17:65-134. -
1402 www.mitoeagle.org/index.php/Chance_1956_Adv_Enzymol_Relat_Subj_Biochem
- 1403 Cobb LJ, Lee C, Xiao J, Yen K, Wong RG, Nakamura HK, Mehta HH, Gao Q, Ashur C,
1404 Huffman DM, Wan J, Muzumdar R, Barzilai N, Cohen P (2016) Naturally occurring
1405 mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin
1406 sensitivity, and inflammatory markers. *Aging (Albany NY)* 8:796-809.
- 1407 Cohen ER, Cvitas T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F,
1408 Quack M, Stohner J, Strauss HL, Takami M, Thor HL (2008) Quantities, units and
1409 symbols in physical chemistry, IUPAC Green Book, 3rd Edition, 2nd Printing, IUPAC &
1410 RSC Publishing, Cambridge. -
1411 www.mitoeagle.org/index.php/Cohen_2008_IUPAC_Green_Book
- 1412 Cooper H, Hedges LV, Valentine JC, eds (2009) The handbook of research synthesis and
1413 meta-analysis. Russell Sage Foundation.

- 1414 Coopersmith J (2010) Energy, the subtle concept. The discovery of Feynman's blocks from
1415 Leibnitz to Einstein. Oxford University Press:400 pp.
- 1416 Cummins J (1998) Mitochondrial DNA in mammalian reproduction. *Rev Reprod* 3:172–82.
- 1417 Dai Q, Shah AA, Garde RV, Yonish BA, Zhang L, Medvitz NA, Miller SE, Hansen EL, Dunn
1418 CN, Price TM (2013) A truncated progesterone receptor (PR-M) localizes to the
1419 mitochondrion and controls cellular respiration. *Mol Endocrinol* 27:741-53.
- 1420 Divakaruni AS, Brand MD (2011) The regulation and physiology of mitochondrial proton
1421 leak. *Physiology (Bethesda)* 26:192-205.
- 1422 Drahota Z, Milerová M, Stieglerová A, Houstek J, Ostádal B (2004) Developmental changes
1423 of cytochrome *c* oxidase and citrate synthase in rat heart homogenate. *Physiol Res*
1424 53:119-22.
- 1425 Duarte FV, Palmeira CM, Rolo AP (2014) The role of microRNAs in mitochondria: small
1426 players acting wide. *Genes (Basel)* 5:865-86.
- 1427 Dufour S, Rouse N, Canioni P, Diolez P (1996) Top-down control analysis of temperature
1428 effect on oxidative phosphorylation. *Biochem J* 314:743-51.
- 1429 Ernster L, Schatz G (1981) Mitochondria: a historical review. *J Cell Biol* 91:227s-55s. -
1430 www.mitoeagle.org/index.php/Ernster_1981_J_Cell_Biol
- 1431 Estabrook RW (1967) Mitochondrial respiratory control and the polarographic measurement
1432 of ADP:O ratios. *Methods Enzymol* 10:41-7. -
1433 www.mitoeagle.org/index.php/Estabrook_1967_Methods_Enzymol
- 1434 Faber C, Zhu ZJ, Castellino S, Wagner DS, Brown RH, Peterson RA, Gates L, Barton J,
1435 Bickett M, Hagerty L, Kimbrough C, Sola M, Bailey D, Jordan H, Elangbam CS (2014)
1436 Cardiolipin profiles as a potential biomarker of mitochondrial health in diet-induced
1437 obese mice subjected to exercise, diet-restriction and ephedrine treatment. *J Appl*
1438 *Toxicol* 34:1122-9.
- 1439 Fell D (1997) Understanding the control of metabolism. Portland Press.

- 1440 Garlid KD, Beavis AD, Ratkje SK (1989) On the nature of ion leaks in energy-transducing
1441 membranes. *Biochim Biophys Acta* 976:109-20. -
1442 www.mitoeagle.org/index.php/Garlid_1989_Biochim_Biophys_Acta
- 1443 Garlid KD, Semrad C, Zinchenko V. Does redox slip contribute significantly to mitochondrial
1444 respiration? In: Schuster S, Rigoulet M, Ouhabi R, Mazat J-P, eds (1993) *Modern trends*
1445 *in biothermokinetics*. Plenum Press, New York, London:287-93.
- 1446 Gerö D, Szabo C (2016) Glucocorticoids suppress mitochondrial oxidant production via
1447 upregulation of uncoupling protein 2 in hyperglycemic endothelial cells. *PLoS One*
1448 11:e0154813.
- 1449 Gnaiger E. Efficiency and power strategies under hypoxia. Is low efficiency at high glycolytic
1450 ATP production a paradox? In: *Surviving Hypoxia: Mechanisms of Control and*
1451 *Adaptation*. Hochachka PW, Lutz PL, Sick T, Rosenthal M, Van den Thillart G, eds
1452 (1993a) CRC Press, Boca Raton, Ann Arbor, London, Tokyo:77-109. -
1453 www.mitoeagle.org/index.php/Gnaiger_1993_Hypoxia
- 1454 Gnaiger E (1993b) Nonequilibrium thermodynamics of energy transformations. *Pure Appl*
1455 *Chem* 65:1983-2002. - www.mitoeagle.org/index.php/Gnaiger_1993_Pure_Appl_Chem
- 1456 Gnaiger E (2001) Bioenergetics at low oxygen: dependence of respiration and
1457 phosphorylation on oxygen and adenosine diphosphate supply. *Respir Physiol* 128:277-
1458 97. - www.mitoeagle.org/index.php/Gnaiger_2001_Respir_Physiol
- 1459 Gnaiger E (2014) Mitochondrial pathways and respiratory control. An introduction to
1460 OXPHOS analysis. 4th ed. *Mitochondr Physiol Network* 19.12. Oroboros MiPNet
1461 Publications, Innsbruck:80 pp. -
1462 www.mitoeagle.org/index.php/Gnaiger_2014_MitoPathways
- 1463 Gnaiger E (2009) Capacity of oxidative phosphorylation in human skeletal muscle. *New*
1464 *perspectives of mitochondrial physiology*. *Int J Biochem Cell Biol* 41:1837-45. -
1465 www.mitoeagle.org/index.php/Gnaiger_2009_Int_J_Biochem_Cell_Biol

- 1466 Gnaiger E, Méndez G, Hand SC (2000) High phosphorylation efficiency and depression of
1467 uncoupled respiration in mitochondria under hypoxia. Proc Natl Acad Sci USA
1468 97:11080-5. -
1469 www.mitoeagle.org/index.php/Gnaiger_2000_Proc_Natl_Acad_Sci_U_S_A
- 1470 Greggio C, Jha P, Kulkarni SS, Lagarrigue S, Broskey NT, Boutant M, Wang X, Conde
1471 Alonso S, Ofori E, Auwerx J, Cantó C, Amati F (2017) Enhanced respiratory chain
1472 supercomplex formation in response to exercise in human skeletal muscle. Cell Metab
1473 25:301-11. - http://www.mitoeagle.org/index.php/Greggio_2017_Cell_Metab
- 1474 Hofstadter DR (1979) Gödel, Escher, Bach: An eternal golden braid. A metaphorical fugue on
1475 minds and machines in the spirit of Lewis Carroll. Harvester Press:499 pp. -
1476 www.mitoeagle.org/index.php/Hofstadter_1979_Harvester_Press
- 1477 Illaste A, Laasmaa M, Peterson P, Vendelin M (2012) Analysis of molecular movement
1478 reveals latticelike obstructions to diffusion in heart muscle cells. Biophys J 102:739-48.
1479 - PMID: 22385844
- 1480 Jasienski M, Bazzaz FA (1999) The fallacy of ratios and the testability of models in biology.
1481 Oikos 84:321-26.
- 1482 Jepihhina N, Beraud N, Sepp M, Birkedal R, Vendelin M (2011) Permeabilized rat
1483 cardiomyocyte response demonstrates intracellular origin of diffusion obstacles.
1484 Biophys J 101:2112-21. - PMID: 22067148
- 1485 Klepinin A, Ounpuu L, Guzun R, Chekulayev V, Timohhina N, Tepp K, Shevchuk I,
1486 Schlattner U, Kaambre T (2016) Simple oxygraphic analysis for the presence of
1487 adenylate kinase 1 and 2 in normal and tumor cells. J Bioenerg Biomembr 48:531-48. -
1488 http://www.mitoeagle.org/index.php/Klepinin_2016_J_Bioenerg_Biomembr
- 1489 Klingenberg M (2017) UCP1 - A sophisticated energy valve. Biochimie 134:19-27.
- 1490 Koit A, Shevchuk I, Ounpuu L, Klepinin A, Chekulayev V, Timohhina N, Tepp K, Puurand
1491 M, Truu L, Heck K, Valvere V, Guzun R, Kaambre T (2017) Mitochondrial respiration

- 1492 in human colorectal and breast cancer clinical material is regulated differently. *Oxid*
1493 *Med Cell Longev* 1372640. -
1494 http://www.mitoeagle.org/index.php/Koit_2017_Oxid_Med_Cell_Longev
- 1495 Komlódi T, Tretter L (2017) Methylene blue stimulates substrate-level phosphorylation
1496 catalysed by succinyl-CoA ligase in the citric acid cycle. *Neuropharmacology* 123:287-
1497 98. - www.mitoeagle.org/index.php/Komlodi_2017_Neuropharmacology
- 1498 Lane N (2005) *Power, sex, suicide: Mitochondria and the meaning of life*. Oxford University
1499 Press:354 pp.
- 1500 Larsen S, Nielsen J, Neigaard Nielsen C, Nielsen LB, Wibrand F, Stride N, Schroder HD,
1501 Boushel RC, Helge JW, Dela F, Hey-Mogensen M (2012) Biomarkers of mitochondrial
1502 content in skeletal muscle of healthy young human subjects. *J Physiol* 590:3349-60. -
1503 http://www.mitoeagle.org/index.php/Larsen_2012_J_Physiol
- 1504 Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener
1505 AL, de Cabo R, Cohen P (2015) The mitochondrial-derived peptide MOTS-c promotes
1506 metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metab* 21:443-
1507 54.
- 1508 Lee SR, Kim HK, Song IS, Youm J, Dizon LA, Jeong SH, Ko TH, Heo HJ, Ko KS, Rhee BD,
1509 Kim N, Han J (2013) Glucocorticoids and their receptors: insights into specific roles in
1510 mitochondria. *Prog Biophys Mol Biol* 112:44-54.
- 1511 Leek BT, Mudaliar SR, Henry R, Mathieu-Costello O, Richardson RS (2001) Effect of acute
1512 exercise on citrate synthase activity in untrained and trained human skeletal muscle. *Am*
1513 *J Physiol Regul Integr Comp Physiol* 280:R441-7.
- 1514 Lemieux H, Blier PU, Gnaiger E (2017) Remodeling pathway control of mitochondrial
1515 respiratory capacity by temperature in mouse heart: electron flow through the Q-
1516 junction in permeabilized fibers. *Sci Rep* 7:2840. -
1517 www.mitoeagle.org/index.php/Lemieux_2017_Sci_Rep

- 1518 Lenaz G, Tioli G, Falasca AI, Genova ML (2017) Respiratory supercomplexes in
1519 mitochondria. In: Mechanisms of primary energy trasduction in biology. M Wikstrom
1520 (ed) Royal Society of Chemistry Publishing, London, UK:296-337.
- 1521 Margulis L (1970) Origin of eukaryotic cells. New Haven: Yale University Press.
- 1522 Meinild Lundby AK, Jacobs RA, Gehrig S, de Leur J, Hauser M, Bonne TC, Flück D,
1523 Dandanell S, Kirk N, Kaech A, Ziegler U, Larsen S, Lundby C (2017) Exercise training
1524 increases skeletal muscle mitochondrial volume density by enlargement of existing
1525 mitochondria and not de novo biogenesis. Acta Physiol (Oxf) [Epub ahead of print].
- 1526 Menshikova EV, Ritov VB, Fairfull L, Ferrell RE, Kelley DE, Goodpaster BH (2006) Effects
1527 of exercise on mitochondrial content and function in aging human skeletal muscle. J
1528 Gerontol A Biol Sci Med Sci 61:534-40.
- 1529 Menshikova EV, Ritov VB, Ferrell RE, Azuma K, Goodpaster BH, Kelley DE (2007)
1530 Characteristics of skeletal muscle mitochondrial biogenesis induced by moderate-
1531 intensity exercise and weight loss in obesity. J Appl Physiol (1985) 103:21-7.
- 1532 Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH, Kelley DE (2005)
1533 Effects of weight loss and physical activity on skeletal muscle mitochondrial function in
1534 obesity. Am J Physiol Endocrinol Metab 288:E818-25.
- 1535 Miller GA (1991) The science of words. Scientific American Library New York:276 pp. -
1536 www.mitoeagle.org/index.php/Miller_1991_Scientific_American_Library
- 1537 Mitchell P (1961) Coupling of phosphorylation to electron and hydrogen transfer by a chemi-
1538 osmotic type of mechanism. Nature 191:144-8. -
1539 http://www.mitoglobal.org/index.php/Mitchell_1961_Nature
- 1540 Mitchell P (2011) Chemiosmotic coupling in oxidative and photosynthetic phosphorylation.
1541 Biochim Biophys Acta Bioenergetics 1807:1507-38. -
1542 <http://www.sciencedirect.com/science/article/pii/S0005272811002283>

- 1543 Mitchell P, Moyle J (1967) Respiration-driven proton translocation in rat liver mitochondria.
1544 Biochem J 105:1147-62. - www.mitoeagle.org/index.php/Mitchell_1967_Biochem_J
- 1545 Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, Højlund K
1546 (2007) Mitochondrial respiration is decreased in skeletal muscle of patients with type 2
1547 diabetes. Diabetes 56:1592-9.
- 1548 Moreno M, Giacco A, Di Munno C, Goglia F (2017) Direct and rapid effects of 3,5-diiodo-L-
1549 thyronine (T2). Mol Cell Endocrinol 7207:30092-8.
- 1550 Morrow RM, Picard M, Derbeneva O, Leipzig J, McManus MJ, Gouspillou G, Barbat-Artigas
1551 S, Dos Santos C, Hepple RT, Murdock DG, Wallace DC (2017) Mitochondrial energy
1552 deficiency leads to hyperproliferation of skeletal muscle mitochondria and enhanced
1553 insulin sensitivity. Proc Natl Acad Sci U S A 114:2705-10. -
1554 www.mitoeagle.org/index.php/Morrow_2017_Proc_Natl_Acad_Sci_U_S_A
- 1555 Nicholls DG, Ferguson S (2013) Bioenergetics 4. Elsevier.
- 1556 Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G (2014) Functional role
1557 of cardiolipin in mitochondrial bioenergetics. Biochim Biophys Acta 1837:408-17. -
1558 http://www.mitoeagle.org/index.php/Paradies_2014_Biochim_Biophys_Acta
- 1559 Pesta D, Hoppel F, Macek C, Messner H, Faulhaber M, Kobel C, Parson W, Burtscher M,
1560 Schocke M, Gnaiger E (2011) Similar qualitative and quantitative changes of
1561 mitochondrial respiration following strength and endurance training in normoxia and
1562 hypoxia in sedentary humans. Am J Physiol Regul Integr Comp Physiol 301:R1078–87.
- 1563 Price TM, Dai Q (2015) The role of a mitochondrial progesterone receptor (PR-M) in
1564 progesterone action. Semin Reprod Med 33:185-94.
- 1565 Prigogine I (1967) Introduction to thermodynamics of irreversible processes. Interscience,
1566 New York, 3rd ed.
- 1567 Puchowicz MA, Varnes ME, Cohen BH, Friedman NR, Kerr DS, Hoppel CL (2004)
1568 Oxidative phosphorylation analysis: assessing the integrated functional activity of

- 1569 human skeletal muscle mitochondria – case studies. *Mitochondrion* 4:377-85. -
- 1570 www.mitoeagle.org/index.php/Puchowicz_2004_Mitochondrion
- 1571 Puntschart A, Claassen H, Jostarndt K, Hoppeler H, Billeter R (1995) mRNAs of enzymes
- 1572 involved in energy metabolism and mtDNA are increased in endurance-trained athletes.
- 1573 *Am J Physiol* 269:C619-25.
- 1574 Quiros PM, Mottis A, Auwerx J (2016) Mitonuclear communication in homeostasis and
- 1575 stress. *Nat Rev Mol Cell Biol* 17:213-26.
- 1576 Reichmann H, Hoppeler H, Mathieu-Costello O, von Bergen F, Pette D (1985) Biochemical
- 1577 and ultrastructural changes of skeletal muscle mitochondria after chronic electrical
- 1578 stimulation in rabbits. *Pflugers Arch* 404:1-9.
- 1579 Renner K, Amberger A, Konwalinka G, Gnaiger E (2003) Changes of mitochondrial
- 1580 respiration, mitochondrial content and cell size after induction of apoptosis in leukemia
- 1581 cells. *Biochim Biophys Acta* 1642:115-23. -
- 1582 www.mitoeagle.org/index.php/Renner_2003_Biochim_Biophys_Acta
- 1583 Rich P (2003) Chemiosmotic coupling: The cost of living. *Nature* 421:583. -
- 1584 www.mitoeagle.org/index.php/Rich_2003_Nature
- 1585 Rostovtseva TK, Sheldon KL, Hassanzadeh E, Monge C, Saks V, Bezrukov SM, Sackett DL
- 1586 (2008) Tubulin binding blocks mitochondrial voltage-dependent anion channel and
- 1587 regulates respiration. *Proc Natl Acad Sci USA* 105:18746-51. -
- 1588 www.mitoeagle.org/index.php/Rostovtseva_2008_Proc_Natl_Acad_Sci_U_S_A
- 1589 Rustin P, Parfait B, Chretien D, Bourgeron T, Djouadi F, Bastin J, Rötig A, Munnich A
- 1590 (1996) Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes
- 1591 in human cultured cells. *J Biol Chem* 271:14785-90.
- 1592 Saks VA, Veksler VI, Kuznetsov AV, Kay L, Sikk P, Tiivel T, Tranqui L, Olivares J, Winkler
- 1593 K, Wiedemann F, Kunz WS (1998) Permeabilised cell and skinned fiber techniques in

- 1594 studies of mitochondrial function in vivo. Mol Cell Biochem 184:81-100. -
- 1595 http://www.mitoeagle.org/index.php/Saks_1998_Mol_Cell_Biochem
- 1596 Salabei JK, Gibb AA, Hill BG (2014) Comprehensive measurement of respiratory activity in
1597 permeabilized cells using extracellular flux analysis. Nat Protoc 9:421-38.
- 1598 Sazanov LA (2015) A giant molecular proton pump: structure and mechanism of respiratory
1599 complex I. Nat Rev Mol Cell Biol 16:375-88. -
- 1600 www.mitoeagle.org/index.php/Sazanov_2015_Nat_Rev_Mol_Cell_Biol
- 1601 Schneider TD (2006) Claude Shannon: biologist. The founder of information theory used
1602 biology to formulate the channel capacity. IEEE Eng Med Biol Mag 25:30-3.
- 1603 Schönfeld P, Dymkowska D, Wojtczak L (2009) Acyl-CoA-induced generation of reactive
1604 oxygen species in mitochondrial preparations is due to the presence of peroxisomes.
1605 Free Radic Biol Med 47:503-9.
- 1606 Schrödinger E (1944) What is life? The physical aspect of the living cell. Cambridge Univ
1607 Press. - www.mitoeagle.org/index.php/Gnaiger_1994_BTK
- 1608 Schultz J, Wiesner RJ (2000) Proliferation of mitochondria in chronically stimulated rabbit
1609 skeletal muscle--transcription of mitochondrial genes and copy number of
1610 mitochondrial DNA. J Bioenerg Biomembr 32:627-34.
- 1611 Simson P, Jepihhina N, Laasmaa M, Peterson P, Birkedal R, Vendelin M (2016) Restricted
1612 ADP movement in cardiomyocytes: Cytosolic diffusion obstacles are complemented
1613 with a small number of open mitochondrial voltage-dependent anion channels. J Mol
1614 Cell Cardiol 97:197-203. - PMID: 27261153
- 1615 Stucki JW, Ineichen EA (1974) Energy dissipation by calcium recycling and the efficiency of
1616 calcium transport in rat-liver mitochondria. Eur J Biochem 48:365-75.
- 1617 Tonkonogi M, Harris B, Sahlin K (1997) Increased activity of citrate synthase in human
1618 skeletal muscle after a single bout of prolonged exercise. Acta Physiol Scand 161:435-
1619 6.

- 1620 Waczulikova I, Habodaszova D, Cagalinec M, Ferko M, Ulicna O, Mateasik A, Sikurova L,
1621 Ziegelhoffer A (2007) Mitochondrial membrane fluidity, potential, and calcium
1622 transients in the myocardium from acute diabetic rats. *Can J Physiol Pharmacol* 85:372-
1623 81.
- 1624 Wagner BA, Venkataraman S, Buettner GR (2011) The rate of oxygen utilization by cells.
1625 *Free Radic Biol Med* 51:700-712. -
1626 <http://dx.doi.org/10.1016/j.freeradbiomed.2011.05.024> PMID: PMC3147247
- 1627 Wang H, Hiatt WR, Barstow TJ, Brass EP (1999) Relationships between muscle
1628 mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in
1629 man: alterations with disease. *Eur J Appl Physiol Occup Physiol* 80:22-7.
- 1630 Wang T (2010) Coulomb force as an entropic force. *Phys Rev D* 81:104045. -
1631 www.mitoeagle.org/index.php/Wang_2010_Phys_Rev_D
- 1632 Watt IN, Montgomery MG, Runswick MJ, Leslie AG, Walker JE (2010) Bioenergetic cost of
1633 making an adenosine triphosphate molecule in animal mitochondria. *Proc Natl Acad Sci*
1634 *U S A* 107:16823-7. -
1635 www.mitoeagle.org/index.php/Watt_2010_Proc_Natl_Acad_Sci_U_S_A
- 1636 Weibel ER, Hoppeler H (2005) Exercise-induced maximal metabolic rate scales with muscle
1637 aerobic capacity. *J Exp Biol* 208:1635–44.
- 1638 White DJ, Wolff JN, Pierson M, Gemmell NJ (2008) Revealing the hidden complexities of
1639 mtDNA inheritance. *Mol Ecol* 17:4925–42.
- 1640 Wikström M, Hummer G (2012) Stoichiometry of proton translocation by respiratory
1641 complex I and its mechanistic implications. *Proc Natl Acad Sci U S A* 109:4431-6. -
1642 www.mitoeagle.org/index.php/Wikstroem_2012_Proc_Natl_Acad_Sci_U_S_A
- 1643 Willis WT, Jackman MR, Messer JJ, Kuzmiak-Glancy S, Glancy B (2016) A simple hydraulic
1644 analog model of oxidative phosphorylation. *Med Sci Sports Exerc* 48:990-1000.